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Abstract: OBJECTIVES Bone grafts are often used to enhance bone volume/quality prior to implantation
insertion. This systematic review compares the histomorphometric effectiveness of bone grafts in an
evidence-based manner. DATA Randomized clinical trials comparing histomorphometrically the % of
newly-formed bone between two grafts were included. Risk of bias within and across studies was assessed
with the Cochrane tool and the GRADE approach, respectively. Random-effects pairwise meta-analyses
were conducted, followed by network meta-analysis, network meta-regression and sensitivity analyses.
SOURCES Four electronic databases were searched from inception to June 2015 without limitations.
STUDY SELECTION A total of 12 trials (5 parallel; 7 cluster) with a total of 231 patients (302 grafted
sites) were included. No statistically significant differences were found in the % of new bone from pairwise
comparisons between any two bone grafts. Treatment ranking based on the evidence network indicated
that autografts presented the highest percentage of new bone, followed by synthetic grafts, xenografts,
and allografts. No differences according to patient age, sex, healing time, membrane used or kind of
surgical graft use were identified. Our confidence on pairwise comparisons was moderate to very low due
to study limitations, inconsistency, and imprecision; our confidence on graft ranking was moderate due
to study limitations. CONCLUSIONS No significant differences were found in the percentage of new
bone between any two grafts. CLINICAL SIGNIFICANCE Synthetic bone substitutes or xenologous
bone grafts can be used as an alternative to autologous graft in order to overcome problems of additional
surgeries or limited graft availability.
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A B S T R A C T  
Objectives: Bone grafts are often used to enhance bone volume / quality prior to implantation insertion. 
This systematic review compares the histomorphometric effectiveness of bone grafts in an evidence-
based manner. 
Data: Randomized clinical trials comparing histomorphometrically the % of newly-formed bone between 
two grafts were included. Risk of bias within and across studies was assessed with the Cochrane tool and 
the GRADE approach, respectively. Random-effects pairwise meta-analyses were conducted, followed by 
network meta-analysis, network meta-regression and sensitivity analyses. 
Sources: Four electronic databases were searched from inception to June 2015 without limitations.  
Study selection: A total of 12 trials (5 parallel; 7 cluster) with a total of 231 patients (302 grafted sites) 
were included. No statistically significant differences were found in the % of new bone from pairwise 
comparisons between any two bone grafts. Treatment ranking based on the evidence network indicated 
that autografts presented the highest % of new bone, followed by synthetic grafts, xenografts, and 
allografts. No differences according to patient age, sex, healing time, membrane used or kind of surgical 
graft use were identified. Our confidence on pairwise comparisons was moderate to very low, due to 
study limitations, inconsistency, and imprecision; our confidence on graft ranking was moderate, due to 
study limitations. 
Conclusions: No significant differences were found in the % of new bone between any two grafts. 
Clinical significance: Synthetic bone substitutes or xenologous bone grafts can be used as an alternative to 







Resorption of the edentulous or partially edentulous alveolar ridge frequently compromises dental 
implant placement in a prosthetically ideal position. Therefore, augmentation of an insufficient bone 
volume is often indicated prior to or in conjunction with implant placement to attain predictable long-
term functioning and an esthetic treatment outcome. Autogenous bone grafts (AUTs) are considered the 
gold standard in bone regeneration procedures [1]. However, donor site morbidity, transmission of live 
viruses, unpredictable resorption, limited quantities available, and the need to include additional surgical 
sites are autografts-related drawbacks that have intensified the search for suitable alternatives [2]. 
Bone-substitute materials have increased in popularity as adjuncts to or replacements for AUTs 
in bone augmentation procedures to overcome many of their limitations [3]. Bone-substitute materials 
can be categorized in three groups: (1) allogenic grafts (ALLs), from another individual within the same 
species; (2) xenogenic grafts (XENs), from another species; or (3) alloplastic, synthetically produced 
grafts (SYNs). According to contemporary trends, the ideal characteristics of a bone-substitute material 
include space maintenance, pre-specification of the desired anatomical form, support to the periosteum, 
acceleration of bone remodeling, osteoconductive guidance, carrier function for antibiotics, growth 
factors or gene therapy approaches or scaffolds for tissue engineering [2,4-6]. It may be too optimistic to 
expect that a single grafting material fulfill all these functions and will be suitable for all indications. 
A large number of systematic reviews with meta-analyses has been published in the last five 
years [7-15], but most were of suboptimal conduct or reporting and / or had methodological limitations 




We conducted a systematic review of parallel and cluster randomized trials (RCTs) including network 
meta-analysis in order to investigate the comparative effectiveness of bone grafts used in oral and 
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maxillofacial surgery prior to implant placement in humans and to compare all grafts with the current 
gold standard (AUT). 
 
2. Materials and Methods 
2.1. Protocol and registration 
The protocol for this review was made a priori based on the PRISMA-P statement [17], registered in 
PROSPERO (CRD42015023467), and all post hoc changes were noted. This systematic review was 
conducted according to Cochrane Handbook [18] and reported according to the newly-published PRISMA 
Extension for network meta-analyses [19]. 
 
2.2. Eligibility criteria and literature search 
RCTs on human patients comparing any two natural or synthetic bone grafts were included. No lumping 
of interventions was performed during the study selection phase. Non-RCTs were excluded, due to bias 
[20-23]. Both parallel (one graft per patient) and clustered trials (>one graft per patient) were included 
and assessed appropriately together, by calculating for the latter clustering-adjusted estimates through 
random-effects regression. The pre-specified eligibiligy criteria can be found in Appendix 1. 
Four electronic databases were searched systematically by one author (SNP) without any 
limitations from inception up to June 15th, 2015 and re-checked in October 2015 for manual additions 
(Appendix 1). Four additional sources (Scopus, Google Scholar, ClinicalTrials.gov, and ISRCTN registry) 
were manually searched for additions. Authors contacted for missing data were asked about additional 
missed trials. No search limitations concerning language, publication year or status were applied, except 
for studies on humans, where available. The reference/citation lists of the included trials and relevant 
systematic reviews were manually searched as well. 
 
2.3. Study selection 
Titles identified were screened by one author (SNP) with a subsequent duplicate independent checking of 
their abstracts/full-texts against the eligibility criteria by two authors (SNP, PNP), while conflicts were 
resolved by a third author (JD). 
 
2.4. Data collection 
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Characteristics of included trials and numerical data were extracted in triplicate by three authors (SNP, 
PNP, JD) using a priori constructed and piloted extraction forms. Lumping of identified grafts was 
performed into four categories: AUT, ALL, SYN, and XEN. In case of combinations of grafts, the graft was 
categorized according to the graft with over 70% contribution (Appendix 1). Piloting of the forms was 
performed during the protocol stage until over 90% agreement was reached. Missing or unclear 
information was requested per e-mail by the trials’ authors. 
 
2.5. Risk of bias in individual trials 
The risk of bias of the included trials was assessed using Cochrane’s risk of bias tool [18] after initial 
calibration by three review authors (SNP, PNP, JD) and any disagreement was discussed with a fourth 
author (WG). The risk of bias assessment for each trial was based on the primary outcome (% new bone) 
or, if this was not included in the trial, on the trial’s primary outcome. The risk of bias was incorporated in 
data synthesis using the framework of Salanti et al. [24]. 
 
2.6. Data synthesis 
As the outcome of bone augmentation could be influenced by the bone graft, the technique, the patient’s 
individual biological response, and post-operative management, a random-effects model according to 
DerSimonian and Laird was deemed appropriate to incorporate this variability [25]. Both pairwise and 
network meta-analyses were conducted to obtain estimates for primary and secondary outcomes, and 
presented as Mean Differences (MDs) or Relative Risks (RRs) with 95% Confidence Intervals (CIs). 
Heterogeneity was conventionally assessed with tau2 and I2 (Appendix 2) and 95% Prediction Intervals 
(PrIs) were calculated to predict effects in a future clinical setting by incorporating heterogeneity. For 
clustered trials, the raw data were requested from the trial’s authors and clustering-adjusted estimates 
were calculated with univariable and multivariable regression. 
The results of all direct and mixed comparisons were presented in league tables and forest plots. 
The latter were augmented with contours of effect magnitude based on multiples of the mean standard 
deviation of the included outcome (10%): 0-10% - clinically-irrelevant effect, 10%-20% - moderate effect, 
20%-30% - large effect, and >30% - very large effect. In order to rank treatments for an outcome, the 
Surface Under the Cumulative RAnking (SUCRA) probabilities were used, which express as a percentage 
the effectiveness of every intervention relative to an imaginary intervention that is always the best 
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without uncertainty [26,27]. Thus, large SUCRA scores indicate a more effective intervention. All analyses 
were done with Stata version 13 (StataCorp, College Station, TX) by one author (SNP), with the commands 
xtgee, metan, mvmeta, network and the routines from Chaimani et al. [28]. A two-tailed P-value of 0.05 
was considered significant for hypothesis-testing. 
The following pre-specified effect modifiers were checked as possible sources of inconsistency / 
heterogeneity at patient or study level with conventional methods (Appendix 2): (a) characteristics of 
patients (age, gender), (b) type of graft, (c) surgical procedure conducted, (d) use of membrane, (e) 
membrane type, and (f) healing time. 
 
2.7. Risk of bias across studies 
The overall quality of clinical recommendations (confidence in effect estimates) for each of the main 
outcomes and for the network was rated using the Grades of Recommendation, Assessment, 
Development, and Evaluation (GRADE) approach, based on the proposal of Salanti et al. [24]. For this 
assessment, the risk of bias of each included trial was re-assessed separately at outcome level. The 
GRADE assessment was performed by one author (SNP) and discussed with the rest (PNP, JD, WG). 
 
2.8. Additional analyses 
Signs of publication bias were planned to be assessed, if ten or more included studies contributed to an 
outcome, with a ‘comparison-adjusted’ funnel plot together with an accompanying statistical test [ 28]; 
this was not performed, as no appropriate treatment ordering by bias-related factors was possible. Small-
study effects were assessed by network meta-regression according to trial size (effect variance). 
Sensitivity analyses were conducted (i) by attempting to form an alternate network geometry 
and to compare its results, (ii) comparing the design-by-treatment model to the original analysis, and (iii) 
examining the basic design of the included studies and its influence. 
 
3. Results 
3.1. Study selection 
The systematic electronic and manual search identified 283 and 7 reports, respectively (Fig 1). From 
these a total of 104 and 167 reports were excluded through screening and fulltext assessment, 
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respectively (Appendix 3). Finally, a total of 45 papers (pertaining to 41 unique trials) were included in 
the systematic review. 
 
3.2. Study characteristics 
The characteristics of the trials included in the qualitative part of this study (i.e. systematic review) can be 
seen in Appendices 4-6. From the 41 included trials 6 (15%) were multicenter and 37 (90%) took place in 
a university environment from 15 different countries. A total of 852 patients (47% male and 53% female) 
were included with an average of 20.8 patients per trial and an average age of 50.6 years. From the 
included trials, 17 (41%) were of parallel design and 24 (59%) of clustered design (i.e. more than one 
grafted site per patient). 
As far as surgical procedures were concerned, 54% of the trials assessed sinus lift, 32% 
preservation of extraction sockets, 12% ridge augmentation, and the last 2% both ridge augmentation 
and sinus lift with a total of 1164 surgical sites being grafted. A wide variety of bone grafts were used, 
which were categorized as AUT (harvested mostly intraorally or from the iliac crest), ALL, SYN (based on 
hydroxyapatite or calcium sulphate), and XEN (mostly represented by Bio-Oss; Geistlich, Wolhusen, 
Switzerland). The grafted region was covered additionally by a membrane (mostly collagen ones) in 56% 
of the trials, by a collagen sponge or fibrin glue in 4% of the trials or without additional means in 37% of 
the trials. 
 In all trials that assessed histomorphometrically the grafted regions, bone samples were collected 
after a healing phase of 3-9 months during a subsequent implant insertion. Among the 25 out of 41 
included trials that adequately reported the subsequent implant insertion, a total of 1261 implants were 
inserted (mean of 50.4 implants per study). 
 
3.3. Risk of bias within studies 
The risk of bias assessment for the 41 included trials can be seen in Appendices 7-9. High risk of bias 
arising from problematic generation of the random sequence was seen in 10% of the trials, bias from 
incomplete outcome data in 7% of the trials, and bias from selective outcome reporting in 5% of the trials. 
The main source of bias however, was residual bias due to other reasons, including poor trial design, 
inadequate data handling for cluster trials or failing to take into account confounding introduced from 
smoking or systemic diseases. It is however important, that extreme uncertainty exists on the bias 
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assessment of random sequence generation, allocation concealment and blinding, as these were very 
poorly reported, making a formal assessment of their appropriateness impossible (“unclear” categories in 
the risk of bias summary). 
 
3.4. Results of individual trials 
The results of the 41 individual trials that were included in the systematic review are expressed as MDs 
or RRs in Appendix 10. In the case of available individual patient data, these are based on univariable or 
multivariable generalized estimating equations accounting for clustering within patients and any possible 
confounders reported in the original trial (patient sex, age, healing time, membrane type). 
  
3.5. Network structure and synthesis of results 
Out of the 41 trials included in the qualitative part of this study (i.e. systematic review), only 12 were 
included in the quantitative synthesis (i.e. meta-analyses) for various reasons (Fig 1). These pertained to 
5 pairwise comparisons (AUT vs ALL, AUT vs SYN, AUT vs XEN, ALL vs SYN, and SYN vs XEN), with most 
of them being statistically insignificant, although high heterogeneity was found (Table 1; Appendix 11). 
When assessing all comparisons for the primary outcome of the review (% of new bone) at the 
same time, a square network of 12 trials, 231 patients and 302 grafted sites was formed (Fig 2). This 
network included the 5 above-mentioned direct comparisons, 1 indirect comparison (ALL vs XEN), and 
additional mixed-treatment information from the whole network (Appendix 12). The assumption of 
transitivity was satisfied on theoretical grounds, as all trials randomized adult patients of similar age and 
sex, and with similar medical background, as the primary outcome measurement pre-included the ability 
to subsequently insert a dental implant. No major violation of transitivity was identified on practical 
ground, as mean ages and the % of sex distribution was relatively similar among all comparisons 
(Appendix 13). The results for all comparisons arising from direct comparisons and from the evidence 
network can be seen in Fig 3 and Appendix 14. All other grafts resulted in lower % of new bone compared 
to AUT, while both SYN and XEN resulted in higher % of new bone compared to ALL. Finally, SYN resulted 
in slightly higher % of new bone compared to XEN, although high heterogeneity existed (tau2 of 141.37) 
and all abovementioned comparisons were statistically non-significant, due to small sample size and wide 
95% CIs. The ranking of the various grafts according to the % of new bone formed is found in Fig 4. As can 
be seen from the SUCRA plots, AUT had the best results, followed by SYN, XEN, and finally ALL. 
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3.6. Exploration of inconsistency 
When inconsistency was checked in a loop-specific approach (Appendix 15), one of the two existing 
closed triangular was inconsistent. Additionally, comparison of direct and indirect estimates (node-
splitting procedure) indicated considerable differences for four out of five comparisons, which were 
almost statistically significant at 5%, despite the very wide confidence intervals, due to the limited 
number of trials (Appendix 16). Data were double-checked and we could not identify any important 
variable that differed across comparisons/loops. However, the number of included studies in all loops 
was typically small, so the extent of inconsistency was not deemed substantial enough. Additionally, the 
comparison of the original analysis (consistency model) with the inconsistency model yielded similar 
results (Appendix 17).  
  
3.7. Risk of bias across studies 
Our confidence in the evidence according to the GRADE approach can be found in Table 2 and Appendix 
18-19. As can be seen, our confidence in pairwise comparisons was moderate to very low, mainly due to 
study limitations, inconsistency, and imprecision. On the other side, confidence in the overall ranking of 
treatments was found to be moderate, due to inherent limitations of the included studies. 
 
3.8. Additional analyses (alternate geometry, subgroup analysis, meta-regression) 
As an additional analysis, we attempted to construct an alternative geometry network by analyzing all 
commercially available SYNs separately (Appendix 20). This resulted however in a markedly inconsistent 
network with sparse connections, which made inferences about the network’s transitivity and coherence 
void. Under this alternate treatment ranking (Appendix 21), AUT was the worst graft in terms of % of new 
bone, which is highly improbable based on direct estimates. Therefore, the analysis of this alternate 
network geometry was discarded as instable.  
The effect of the various confounding covariates (patient sex, patient age, type of membrane, and 
healing time) from individual patient data can be seen in Appendix 22. After calculating the effect of each 
covariate on the primary outcome within-trials from raw data, and pooling across-trials, no significant 
modifying effect could be found (P>0.05). The single exception was the type of membrane used over the 
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graft, where the expanded polytetrafluoroethylene membrane was associated with lower % of new bone 
compared to the acellular dermal matrix allograft membrane (P=0.040). 
Network meta-regression was undertaken in order to address the impact of possible confounders 
on the network in a universal scale. As can be seen in Appendix 17, the model fit was not influenced by 
surgery type (socket preservetation, sinus lift or combination procedures), but was affected by the use of 
membranes over the grafts. However, treatment rankings based on the original analysis or on analysis 
adjusting for use of membrane (or not) for the primary and secondary outcomes studied were almost 
exactly the same. The slight variation in the treatment ranking regarding % of new bone was discarded as 
non-credible, as it contradicted with direct evidence of AUT’s superiority, and therefore, the modifying 
effect of membrane use was deemed insignificant. 
 
3.9. Secondary outcomes 
A large number of outcomes were reported from the included studies (Appendix 10), which are however 
only briefly discussed, as they did not refer to histomorphometry and therefore were not the main focus 
of this review. 
As far as secondary histomorphometry outcomes are concerned, many trials also reported the % 
residual graft particles and the % connective tissue from the samples harvested prior to implant insertion 
(Appendix 23). The evidence network and the contribution plots (Appendices 24-25) for these two 
outcomes was similar to the network for the primary outcome (% of new bone). Both networks for the % 
residual graft particles and the % connective tissue presented considerable heterogeneity (tau2 of 106.30 
and 73.62), respectively. AUT and XEN were ranked as equally probable to be the best grafts in terms of 
having the least % of residual graft particles, while AUT and ALL were equally probable to be the be in 
terms of % of connective tissue (Appendix 26). However, the ranking in places 2-3 was SYN-ALL and XEN-
SYN for % of residual graft and % of connective tissue, respectively. When the primary outcome of % new 
bone and the secondary outcome of % residual graft were taken into account at the same time in a 
clustered ranking plot (Appendix 27), AUT was the best graft, while SYN and XEN were relatively 
comparable in terms of effectiveness, and ALL was the worst. Finally, node-splitting analysis regarding 
these two secondary outcomes (Appendix 28) did not identify any serious threats to consistency, 




4.1. Summary of evidence 
This systematic review assessed in an evidence-based matter the histomorphometric effects of various 
bone grafts in sinus lift, extraction socket preservation, and ridge augmentation in human patients prior 
to the insertion of dental implants. Using a network meta-analysis approach, no statistically significant 
differences could be found for most of the histomorphometric outcomes, although this was probably due 
to few included studies and subsequently wide CIs. Based on the evidence network, it could be shown that 
AUTs is the gold standard both in terms of new bone formation and graft integration, which agrees with 
existing knowledge [1]. The same clear distinction could be made for ALL, which was the worst graft 
family studied for both bone formation and graft resorption. As far as SYN and XEN are concerned, they 
formed an intermediate category, where SYN was associated with higher bone formation and lower graft 
resorption, while the opposite was found for XEN. 
SYNs used in oral and maxillofacial surgery have been reported to be bioabsorbable and non-
toxic [29] with a chemical structure similar to bone mineral composition. Previous studies have reported 
that osteoclast-like cells (or foreign body giant cells [30]) can be observed both along the surface of 
newly-formed bone and directly on the graft granules during the healing phase [31-35]. Additionally, 
certain SYNs (bioactive glasses) have been reported to become coated by a calcium-phospate layer in vivo 
and to form a direct chemical bond to bone [29]. Certain modern XENs in the nanometer range like Ostim 
(Heraeus Kulzer GmbH, Hanau, Germany) or NanoBone (Artoss GmbH, Rostock Germany) might also lead 
to a significant increase in contact surface area and thereby result in augmented new bone regeneration 
[36,37]. The single identified trial however, that directly compared Ostim to another SYN (SINTLife, 
FinCeramica, Faenza, Italy) did not find considerable differences [38]. Based on this network meta-
analysis, SYN was the second best graft in terms of % new bone, which was about 5.5% lower than AUT, 
4.9% higher than XEN, and 8.0% higher than ALL. 
XENs, and its most widely known commercial product Bio-Oss (Geistlich Pharma AG, Wolhusen, 
Switzerland), have been successfully used in several studies to preserve ridge dimensions following tooth 
extraction [34,39] and have been proven biocompatible and osteoconductive [40], as their structure and 
surface area promote capillary ingrowth and migration and proliferation of osteoblasts [41,42]. On the 
other hand, some studies have reported delayed healing regions grafted with XEN [42,43]. In the present 
analysis, XENs were the closely tied to the first or second best place after AUTs, with slightly lower % of 
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new bone (-4.9%) and slightly higher % of resorption of graft particles (+2.3%) than SYNs, which 
indicated acceptable biocompatibility and effectiveness. 
Both osteoinductive and osteoconductive properties [44,45], as well as the preservation of bone 
morphogenetic proteins [46] have been attributed to ALLs used in oral surgery. However, a higher 
percentage of residual graft particles and less new bone formation in ALL-graft bone biopsies compared 
to other grafts has also been reported [47], which agrees with our results. ALL was the least effective graft 
than all other, which combined with the lack of osteogenic properties [48], and the risk of transmission of 
infectious agents, malignancies, systemic disorders (autoimmune disease), or toxins [2] render them a 
less appealing alternative to bone grafting. In the present analysis ALLs were the worst graft in terms of 
% new bone, which was 13.5% lower than AUT, 8.0% lower than SYN, and 3% lower than XEN. 
  
4.2. Strengths and limitations 
This systematic review has several strengths, including the a priori registration of its protocol, 
unrestricted literature search, attempts to maximize data output through communication with trial 
authors (Appendix 29), triplicate review procedures with reporting of any deviations from protocol 
(Appendix 30), use of individual patient data (where applicable), adjustment of effect estimates for 
confounders through multivariable regression, simultaneous synthesis of all available evidence by 
network meta-analysis, and formal assessment of our confidence in the overall quality of evidence with 
the GRADE approach. 
However, several limitations also exist. First of all, only some of the data requests were answered 
from trialists, leading certain cluster-trials to be excluded due to incomplete reporting. Additionally, the 
reporting completeness of many identified trials was problematic, which precluded robust assessment of 
the risk of bias. Furthermore, the limited number of trials included in each combination of nodes makes 
difficult to robustly evaluate the transitivity and consistency of the network. The network could have 
been broken down to include all commercially-available grafts separately (Appendix 20), but this was 
problematic, due to the scarcity of most comparisons. Alternatively, partially-available individual patient 
data could have been combined with aggregate data within a Bayesian framework to increase precision 
[49] or a three-level hierarchical level Bayesian analysis could have been used to test across classes and 
subclasses of grafts simultaneously [50]. The test for inconsistency and the meta-regressions were 
likewise affected by this scarcity of trial and their large sampling errors due to small samples, as was seen 
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by their wide confidence intervals. Additionally, the use of a Bayesian framework with an informative 
prior could alleviate some of the high heterogeneity/imprecision of the network. Therefore, caution is 
warranted by the interpretation of these tests, as lack of power and the subsequent imprecision might 
“mask” an existing effect. Finally, for most trials the risk of bias was either unclear or high. 
The findings of this review could be generalizable to most systematically healthy patients, where 
bone grafting is needed for a surgical procedure (sinus lift, preservation of an extraction socket or ridge 
augmentation) prior to implant placement. Although smokers were not excluded, this was deemed as a 
factor that could possibly introduce bias, due to impaired wound healing [51]. The results of this review 
might not be applicable to patients receiving bone grafting simultaneously with implant placement or 
bone grafting of periodontal defects. However, taking into account the abovementioned limitations, the 
generalizability of this review’s findings should be viewed with caution. 
 
4.3. Conclusions 
According to mixed comparisons from randomized controlled trials of bone grafting in humans prior to 
implant insertion, no statistically significant differences could be found for any of the pairwise 
comparisons, although our confidence in these estimates is moderate to very low, mainly due to study 
limitations, inconsistency, and imprecision. 
 
According to the ranking of available grafts based on the evidence network (moderate confidence): 
 Autologous grafts presented the highest % of newly-formed bone, followed by synthetic grafts, 
xenologous grafts, and allogeneic grafts. 
 Autologous grafts presented the lowest % of residual graft particles, followed by xenologous 
grafts, synthetic grafts, and allogeneic grafts. 
 Autologous grafts presented the lowest % of connective tissue, followed by allogeneic grafts, 
xenologous grafts, and synthetic grafts. 
 
4.4. Recommendations for clinical practice 
Taking into account the extra burden of an additional surgery of the gold standard (autologous grafts) 
and the suboptimal performance of allogeneic grafts, synthetic or xenologous bone grafts can be 
considered as an alternative. Synthetic bone grafts are associated with increased bone formation, but 
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lower graft resorption compared to xenologous bone grafts. However, these recommendations should be 
viewed with caution, due to the limitations of the present study. 
 
4.5. Recommendations for further research 
Existing evidence is based on limited trials of small samples with unclear reporting of design 
characteristics. Researchers are encouraged to conduct additional adequately powered randomized trials 
with clear reporting based on the CONSORT statement [52]. As far as consolidation of the evidence 
network is concerned, trials comparing different synthetic bone substitutes with autologous or 
xenologous bone grafts are needed, in order to enable ranking of the separate commercially-available 
grafts. 
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Tables 
Table 1 - Direct estimates of the primary outcome. AUT = autograft; ALL = allograft; SYN = synthetic bone 
graft; XEN = xenograft; MD = mean difference; CI = confidence interval; UI = uncertainty interval; PrI = 
predictive interval. 
Comparison Studies MD (95% CI) I2 (95% UI) tau2 95% PrI P 
AUT-ALL 2 -6.00 (-19.42,7.41) 87% (-) 82.75 - 0.380 
AUT-SYN 2 -4.42 (-9.75,0.91) 68% (-) 10.09 - 0.104 
AUT-XEN 2 -21.62 (-56.40,13.16) 93% (-) 587.86 - 0.223 
ALL-SYN 1 25.33 (13.59,37.07) - 0.00 - <0.001 
SYN-XEN 5 0.90 (-8.75,10.55) 94% (89%,96%) 97.78 -34.25,36.05 0.855 
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Table 2 - Summary of our confidence in effect estimates and ranking of treatments according to the 
GRADE approach. 
Comparison 
Nature of the 
evidence 
Confidence Downgrading due to a  
Autograft vs allograft Mixed Low Imprecision 
Autograft vs synthetic graft Mixed Moderate Imprecision 
Autograft vs xenograft Mixed Very low 
Study limitations; inconsistency; 
imprecision 
Allograft vs synthetic graft Mixed Very low Inconsistency; imprecision 
Allograft vs xenograft Indirect Very low Study limitations; imprecision 
Synthetic graft vs xenograft Mixed Very low 
Study limitations; inconsistency; 
imprecision 
Ranking of treatments  Moderate Study limitations 









Fig. 2 – Network diagram for the primary outcome of % new bone (12 studies; 231patients; 302 grafted sites). Joining lines indicate where head-to-head trials 
between interventions were identified and their risk of bias: green (low risk), yellow (moderate risk), and red (high risk). On each adjoining line is represented the 
number of contributing trials (number) and patients (number in parenthesis) for each comparison. Treatment nodes are proportionally sized to reflect the number 




Fig. 3 – Predictive interval plot for the primary outcome network. The black solid lines represent the confidence intervals for the summary mean difference for each 
comparison and the dotted red lines the respective predictive intervals (possible values in a future trial). The blue vertical line is the line of no effect (mean 




Fig. 4 – Plots of the surface under the cumulative ranking curves for all treatments in the primary outcome network. AUT = autograft; SYN = synthetic bone graft; 
XEN = xenograft; ALL = allograft. 
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Comparative effectiveness of natural and synthetic bone grafts in oral and maxillofacial surgery prior to insertion of dental implants: 
systematic review and network meta-analysis of parallel and cluster randomized controlled trials  
Appendix 1. Pre-defined inclusion and exclusion criteria according to the Participants-Intervention-Comparison-Outcomes-Study design schema and search strategy used in every electronic database together with its results 
(last search June 2015). 
 Inclusion Exclusion 
Participants Patients of any age or sex in need of bone augmentation/preservation procedures in the oral cavity Animal and in vitro studies. 
Intervention 
 Any kind of bone graft or filling material used for ridge augmentation, sinus lift, socket preservation or any other 
bone-augmenting procedure. 
 Combinations of grafts (almost universally of a non-autologous graft with some autologous graft) were eligible, only if 
the actual % contribution of each graft to the combination was reported. In this case, we classified the combination to 
the graft providing over 70% of the whole. 
 In case of graft combinations with equal (i.e. 50%-70%) contributions from their components, the graft was not 
classified in a graft category and the trial was included in the descriptive part, but not in the quantitative one. 
 In case a trial did not report the contribution of each graft to a graft-combination, we included this study in the 
descriptive part, but not in the quantitative synthesis. 
 Membranes or other materials used to cover the surgical site will be eligible, but only if their use is consistent in all 
experimental groups. 
 Studies that utilize immediate implant placement will be excluded, as 
all included studies will have to utilize only bone-augmenting 
procedures without any factor that could possibly intervene to bone 
healing. 
 Studies that investigate the use of bone grafts on already inserted 
dental implants will also be excluded. 
Bone grafting for periapical endodontic lesions or periodontic tooth 
lesions will also be excluded, due to the risk of possibly impaired 
wound healing / bone formation. 
Comparison Any kind of bone graft or filling material. 
Untreated control groups will be excluded, as aim of this review is to 
assess the comparative effectiveness of bone grafts. The absolute effects of 
bone grafting have long been proved. 
Outcome - primary 
The primary outcome will be the % of newly formed bone as measured through histomorphometric analyses of acquired 
bone samples from the augmented sites. We will include all reported time-points after the surgical procedure and we 
will stratify them, if possible. We anticipate that most assessments of newly-formed bone will take place during a 
subsequent stage of implant insertion. 
- 
Outcome - secondary 
 % of remaining graft in the sample 
 % of immature and mature bone in the sample 
 % of soft tissues in the sample 
 any clinical or radiological measurement of bone status 
 adverse effects during the healing phase or afterwards 
 any outcome of periodontal health at the augmented or adjacent sites 
 success and survival of dental implants inserted in the augmented bone on a secondary timepoint. 
- 
Study design Randomized controlled trials (both parallel and clustered) in any clinical setting. Non-randomized or non-clinical studies. 
Literature search 
Database Search Limit Hits 
MEDLINE (through 
Pubmed) 
(hydroxyapatite OR hydroxiapatite) AND ("bone substitute") OR ("bone graft") OR ("bone ceramic") OR ("ceramic 
bone") OR ("bone substitute") OR ("bone substitute healing") OR ("bone tissue engineering") OR ("artificial bone")) AND 
(("dental") OR ("dentistry") OR ("maxillofacial surgery") OR ("oral maxillofacial surgery") OR ("oral surgery") OR ("sinus 
lift")) 
Randomized Controlled Trial; Humans 217 
Cochrane Library 
(CENTRAL) 
(hydroxyapatite OR hydroxiapatite) AND ("bone substitute" OR "bone graft" OR "bone ceramic" OR "ceramic bone" OR 
"bone substitute" OR "bone substitute healing" OR "bone tissue engineering" OR "artificial bone") AND ("dental" OR 
"dentistry" OR "maxillofacial surgery" OR "oral maxillofacial surgery" OR "oral surgery" OR "sinus lift") 
- 47 
Web of Knowledge 
(hydroxyapatite OR hydroxiapatite) AND ("bone substitute" OR "bone graft" OR "bone ceramic" OR "ceramic bone" OR 
"bone substitute" OR "bone substitute healing" OR "bone tissue engineering" OR "artificial bone") AND ("dental" OR 
"dentistry" OR "maxillofacial surgery" OR "oral maxillofacial surgery" OR "oral surgery" OR "sinus lift") AND random* 
Dentistry oral surgery medicine 18 
Virtual Health Library 
(hydroxyapatite OR hydroxiapatite) AND ("bone substitute" OR "bone graft" OR "bone ceramic" OR "ceramic bone" OR 
"bone substitute" OR "bone substitute healing" OR "bone tissue engineering" OR "artificial bone") AND ("dental" OR 
"dentistry" OR "maxillofacial surgery" OR "oral maxillofacial surgery" OR "oral surgery" OR "sinus lift") AND random* 
Limit to humans; exclude MEDLINE+CENTRAL 1 
2 
Appendix 2. Details of data synthesis and assessments of heterogeneity. 
 
Heterogeneity in pairwise analyses was assessed with the I² metric, defined as the proportion of total 
variability in the results explained by heterogeneity, and not chance (Higgins and Thompson 2002). The 
95% uncertainty intervals (95% UI) (similar to CIs) around the I2 were calculated (Ioannidis et al. 2007) 
using the non-central χ2 approximation of Q. For network meta-analysis, a common heterogeneity 
variable for all comparisons (tau) was assumed, which is the estimated standard deviation of underlying 
effects of treatment across studies in a meta-analysis (Salanti, 2012). 
The absolute and relative presence of heterogeneity within pairwise meta-analyses was 
calcuated with the tau2 metric and I² statistic, respectively. I² thresholds were considered to represent 
heterogeneity that might not be important (0% to 40%), might be moderate heterogeneity (30% to 60%), 
might be substantial heterogeneity (50% to 90%), and might be considerable heterogeneity (75% to 
100%), considering also the magnitude and direction of treatment effects and strength of evidence for 
heterogeneity. 
The assumption of transitivity within the network was assessed by exploring the distribution of 
patient characteristics, similarity of interventions, and study design across comparisons.  Based on the 
specific inclusion/exclusion criteria set, only adult patients (since insertion of dental implants is contra-
indicated in growing patients), with similar level of oral hygiene (having experienced tooth loss – i.e. in 
need of dental implants), and with similar medical history (compatible with the surgical insertion of 
implants) were included. Therefore, as all only randomized trials with general patient inclusion criteria 
were included in this systematic review, small deviations to patient characteristics are more likely to be 
due to chance, rather than real clinical inhomogeneity.   
Evidence for consistency in the network was assessed in two ways. First, a loop-specific approach 
was used to investigate consistency within every closed triangular or quadratic loop in every network as 
the difference between direct and indirect estimates for a specific treatment comparison (inconsistency 
factor) in the loop (Salanti et al., 2009). Inconsistent loops were identified as those yielding a 95% CI 
excluding zero. Second, the network-wide method of node-splitting was employed on a frequentist 
framework (Dias et al., 2010) to separates evidence on a particular comparison into “direct” and 
“indirect”, by excluding one direct comparison at a time and estimating the indirect treatment effect for 
the excluded comparison (network sidesplit macro in Stata). Finally, the design-by-treatment interaction 
3 
model was used that provides a single inference, using a χ² test, about the plausibility of assuming 
consistency throughout the entire network and the model fit was compared to the original analysis 
(Higgins et al., 2012). 
On a patient level, we made use of available raw data and fitted multivariable regression models 
to calculate the impact of any effect modifiers on the primary outcome. We then pooled the impact from 
each study across all studies to estimate its overall impact with random-effects meta-analyses. On a study 
level, we performed network meta-regression to explore sources of heterogeneity and/or inconsistency. 
When potential evidence of heterogeneity was identified, we first checked for any mistakes and 
inconsistencies in data extraction and entry. We then evaluated if the network meta-regression model fit 
was substantial altered compared to the original (by reestimating the models by maximum likelihood and 
performing a likelihood ratio test) and if so, treatments were re-ranked. 
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Appendix 3. List of excluded and included studies. 
Nr. Paper Status 
Excluded reports 
1 
AboElsaad NS, Soory M, Gadalla LM, Ragab LI, Dunne S, Zalata KR, et al. Effect of soft laser and bioactive glass on bone regeneration in the treatment 
of infra-bony defects (a clinical study). Lasers in medical science. 2009;24(3):387-95. 
Excluded by title/abstract 
2 
Abrahamsson P, Walivaara DA, Isaksson S, Andersson G. Periosteal expansion before local bone reconstruction using a new technique for measuring 
soft tissue profile stability: a clinical study. Journal of oral and maxillofacial surgery. 2012;70(10):e521-30. 
Excluded by title/abstract 
3 
Agarwal A, Gupta ND. Comparative evaluation of decalcified freeze-dried bone allograft use alone and in combination with polylactic acid, polyglycolic 
acid membrane in the treatment of noncontained human periodontal infrabony defects. Quintessence international (Berlin, Germany : 1985). 
2012;43(9):761-8. Epub 2012/10/09. 
Excluded by title/abstract 
4 
Aimetti M, Pigella E, Romano F, Debernardi C. Treatment of mandibular class II furcation defects by the use of amelogenins and autologous bone. Two 
case reports. Minerva stomatologica. 2005;54(10):583-91. Epub 2005/10/15. 
Excluded by title/abstract 
5 
Alonso N, Tanikawa DY, Freitas Rda S, Canan L, Jr., Ozawa TO, Rocha DL. Evaluation of maxillary alveolar reconstruction using a resorbable collagen 
sponge with recombinant human bone morphogenetic protein-2 in cleft lip and palate patients. Tissue engineering Part C, Methods. 
2010;16(5):1183-9. Epub 2010/02/19. 
Excluded by title/abstract 
6 
Annen BM, Ramel CF, Hammerle CH, Jung RE. Use of a new cross-linked collagen membrane for the treatment of peri-implant dehiscence defects: a 
randomised controlled double-blinded clinical trial. European journal of oral implantology. 2011;4(2):87-100. Epub 2011/08/03. 
Excluded by title/abstract 
7 
Antoun H, Sitbon JM, Martinez H, Missika P. A prospective randomized study comparing two techniques of bone augmentation: onlay graft alone or 
associated with a membrane. Clinical oral implants research. 2001;12(6):632-9. Epub 2001/12/12. 
Excluded by title/abstract 
8 
Barone A, Orlando B, Cingano L, Marconcini S, Derchi G, Covani U. A randomized clinical trial to evaluate and compare implants placed in augmented 
versus non-augmented extraction sockets: 3-year results. Journal of periodontology. 2012;83(7):836-46. Epub 2011/12/07. 
Excluded by title/abstract 
9 
Becker J, Al-Nawas B, Klein MO, Schliephake H, Terheyden H, Schwarz F. Use of a new cross-linked collagen membrane for the treatment of 
dehiscence-type defects at titanium implants: a prospective, randomized-controlled double-blinded clinical multicenter study. Clinical oral implants 
research. 2009;20(7):742-9. Epub 2009/03/24. 
Excluded by title/abstract 
10 
Bettega G, Cinquin P, Lebeau J, Raphael B. Computer-assisted orthognathic surgery: clinical evaluation of a mandibular condyle repositioning system. 
Journal of oral and maxillofacial surgery. 2002;60(1):27-34; discussion -5. Epub 2002/01/05. 
Excluded by title/abstract 
11 
Blaszczyszyn A, Kubasiewicz-Ross P, Gedrange T, Dominiak M. Influence of semipermanent cement application used in immediately loaded, implant-
supported restorations on crestal bone resorption. Annales Academiae Medicae Stetinensis. 2013;59(1):66-75. Epub 2013/01/01. 
Excluded by title/abstract 
12 
Boëck-Neto RJ, Gabrielli M, Lia R, Marcantonio E, Shibli JA. Histomorphometrical analysis of bone formed after maxillary sinus floor augmentation by 
grafting with a combination of autogenous bone and demineralized freeze-dried bone allograft or hydroxyapatite. Journal of periodontology 
[Internet]. 2002; (3):[266-70 pp.]. 
Excluded by title/abstract 
13 
Borges FL, Dias RO, Piattelli A, Onuma T, Gouveia Cardoso LA, Salomao M, et al. Simultaneous sinus membrane elevation and dental implant 
placement without bone graft: a 6-month follow-up study. Journal of periodontology. 2011;82(3):403-12. Epub 2010/11/09. 
Excluded by title/abstract 
14 
Brkovic BM, Prasad HS, Rohrer MD, Konandreas G, Agrogiannis G, Antunovic D, et al. Beta-tricalcium phosphate/type I collagen cones with or without 
a barrier membrane in human extraction socket healing: clinical, histologic, histomorphometric, and immunohistochemical evaluation. Clinical oral 
investigations. 2012;16(2):581-90. Epub 2011/03/04. 
Excluded by title/abstract 
15 
Burger EA, Meshkini H, Lindeboom JA. One versus two titanium screw fixation of autologous onlay bone grafts in the anterior maxilla: a randomised 
histological pilot study. European journal of oral implantology. 2011;4(3):219-25. Epub 2011/11/02. 
Excluded by title/abstract 
16 
Butz F, Bachle M, Ofer M, Marquardt K, Kohal RJ. Sinus augmentation with bovine hydroxyapatite/synthetic peptide in a sodium hyaluronate carrier 
(PepGen P-15 Putty): a clinical investigation of different healing times. International journal of oral & maxillofacial implants [Internet]. 2011; 
(6):[1317-23 pp.]. 
Excluded by title/abstract 
17 
Calongne KB, Aichelmann-Reidy ME, Yukna RA, Mayer ET. Clinical comparison of microporous biocompatible composite of PMMA, PHEMA and 
calcium hydroxide grafts and expanded polytetrafluoroethylene barrier membranes in human mandibular molar Class II furcations. A case series. 
Journal of periodontology. 2001;72(10):1451-9. Epub 2001/11/09. 
Excluded by title/abstract 
18 
Canullo L, Dellavia C. Sinus lift using a nanocrystalline hydroxyapatite silica gel in severely resorbed maxillae: histological preliminary study. Clinical 
implant dentistry and related research. 2009;11 Suppl 1:e7-13. Epub 2009/02/18. 
Excluded by title/abstract 
19 
Chen CC, Wang HL, Smith F, Glickman GN, Shyr Y, O'Neal RB. Evaluation of a collagen membrane with and without bone grafts in treating periodontal 
intrabony defects. Journal of periodontology. 1995;66(10):838-47. Epub 1995/10/01. 
Excluded by title/abstract 
5 
20 
Choi BH, Yoo JH, Sung KJ. Radiographic comparison of osseous healing after maxillary sinusotomy performed with and without a periosteal pedicle. 
Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics. 1996;82(4):375-8. Epub 1996/10/01. 
Excluded by title/abstract 
21 
Choi KS, Kan JY, Boyne PJ, Goodacre CJ, Lozada JL, Rungcharassaeng K. The effects of resorbable membrane on human maxillary sinus graft: a pilot 
study. The International journal of oral & maxillofacial implants. 2009;24(1):73-80. Epub 2009/04/07. 
Excluded by title/abstract 
22 
Cordaro L, Bosshardt DD, Palattella P, Rao W, Serino G, Chiapasco M. Maxillary sinus grafting with Bio-Oss (R) or Straumann (R) Bone Ceramic: 
histomorphometric results from a randomized controlled multicenter clinical trial. Clinical oral implants research. 2008;19(8):796-803. 
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immediate placement of transmucosal implants: a short-term controlled clinical trial. Int J Periodont Restor Dent. 2004;24(6):555-63. 
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Excluded by title/abstract 
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 Cluster trials       
1 Bettega 2009 No Clinic No France 18 (5/13) 50.5 
2 Cordaro 2008 Yes University/practice No Italy 37 (NR) NR 
3 Corinaldesi 2013 No University No Italy 9 (3/6) 50.0 
4 Crespi 2009a$ No University No Italy 15 (8/7) 51.3 
5 Crespi 2009b No University No Italy 15 (9/6) 54.2 
6 Crespi 2011$ No University No Italy 15 (7/8) 53.7 
7 Felice 2008 No University No Italy 10 (4/6) 54.0 
8 Froum 2002$ No University Yes USA 19 (12/7) NR 
9 Froum 2004$ No University Yes USA 15 (9/6) 48.1 
10 Froum 2008 No University Yes USA 12 (NR) NR 
11 Garlini 2014 No University Yes Italy 5 (2/3) 57.0 
12 Gholami 2012 No NR No Iran 12 (4/8) 44.6 
13 Kotsakis 2014$ No University No USA 18 (12/6) 41.6 
14 Lee 2008 No Practice Yes USA 41 (14/27) 59.0 
15 Molly 2008$ No University No Belgium 8 (1/7) 53.0 
16 Mordenfeld 2014 No University No Sweden 13 (6/7) 59.6 
17 Raghoebar 2005 No University No Netherlands 5 (2/3) 58.4 
18 Rickert 2011 No University Yes Netherlands 12 (NR) 60.8 
19 Schmitt 2013 No University No Germany 30 (13/17) NR 
20 Shirmohammadi 2014 No University Yes Iran 10 (8/2) 54.0 
21 Szabo 2005 Yes University/hospital Yes Belgium, Hungary, Italy, UK 20 (9/11) 52.0 
22 Wagner 2012% Yes University/hospital No Germany 32 (NR) NR 
23 Wiltfang 2003 Yes University No Germany 39 (NR) 46.0 
24 Xavier 2014 No University Yes Brazil 15 (8/7) 54.0 
 Parallel trials 
      
25 Calasans-Maia 2013 No University - Brazil 20 (7/13) 44.6 
26 Checci 2011 No University - Italy 10 (0/10) 51.0 
27 Cordaro 2011 No University - Italy 17 (NR) 42.0 
28 de Freitas 2013 No University - Brasil 24 (10/14) 45.1 
29 Galindo-Moreno 2011 No University - Spain 28 (18/10) 47.3 
30 Hermund 2012 No University - Denmark 20 (9/11) 59.5 
31 Jun 2014 No University - Republic of Korea 38 (24/14) 58.2 
32 Koch 2010; Stavropoulos 2011 Yes University - Germany 20 (NR) NR 
33 Kuhl 2012; Kuhl 2013 No University - Germany 23 (10/13) 53.0 
34 Kurkcu 2012 No University - Turkey 23 (12/11) 48.7 
35 
Mardas 2010; Mardas 2011; 
Patel 2013 
No University - UK 27 (6/21) 37.3 
36 Meijndert 2005 # No University - Netherlands 10 (5/5) 35.2 
37 Meijndert 2008 # Yes University/hospital - Netherlands 62 (31/31) 33.4 
38 Piattelli 2002 No University - Italy 18 (12/6) 49.0 
39 Pikdoken 2011 No 
Military medical 
academy 
- Turkey 24 (15/9) 58.9 
40 Tosta 2013 No University - Brasil 30 (NR) NR 
41 Wood 2012 No University - USA 33 (13/20) 56.7 
M, male; F, female; yrs, years; USA, United States of America; UK, United Kingdom; NR, not reported. 
$, some data from ungrafted control group omitted. 
%, some data from patients receiving only one graft material are omitted. 
#, some data due to inconsistent membrane use omitted. 
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Appendix 5. Characteristics of the 41 trials included in this systematic review. 




 Cluster trials        
1 Bettega 2009 SL 36 
-AUT (iliac) 
-AUT (iliac)/PRP/fibrin glue 
-Fibrin glue 
-Fibrin glue+PRP 
111 6 Internal 
2 Cordaro 2008 SL 47 
-XEN (Bio-Oss) 
-SYN: BCP (BoneCeramic) 
Collagen membrane 109 6-8 NR 
3 Corinaldesi 2013 SL 18 
-XEN (Bio-Oss) 
-XEN (Bio-Oss)+GF: eptotermin (Osigraf) 
Collagen membrane NR 4 
Material 
donation 
4 Crespi 2009a $ ESP 30 
-SYN: HA (Sintlife)$ 
-SYN: CS (Easy Set) 
Collagen membrane NR 3 None 
5 Crespi 2009b SL 30 
-AUT (mandible) 
-SYN: HA (Sintlife) 
- 60 5 None 
6 Crespi 2011 $ ESP 30 
-XEN (Tecnoss)$ 
-SYN: HA (Sintlife) 
Collagen membrane 30 4 NR 
7 Felice 2008 VRA 20 
-AUT (iliac) 
-XEN (Bio-Oss) 
Collagen membrane 40 4 
Material 
donation 
8 Froum 2002 $ ESP 20 
-ALL$ 
-SYN: BG (Biogran) 
- 20 6-8 
Commercial 
support 
9 Froum 2004 $ ESP 20 
-XEN (Osteograf R/N300) 
-SYN: HA (Osteograf R/LD) 





10 Froum 2008 SL 24 
-XEN (Bio-Oss) 
-SYN: BCP (BoneCeramic) 
Collagen membrane NR 6-8 
Commercial 
support 
11 Garlini 2014 SL 10 
-XEN (Bio-Oss) 
-SYN: HA (Algipore) 
Collagen membrane 14 6-8 None 
12 Gholami 2012 ESP 24 
-SYN: HA (NanoBone) 
-SYN: HA (Algipore) 
Collagen membrane 24 6-8 NR 
13 Kotsakis 2014 $ ESP 24 
-XEN (Bio-Oss)+collagen plug 
-SYN: CP (NovaBone) 




14 Lee 2008 SL 52 
-AUT (misc)+allograft (Puros) 
-AUT (misc)+xenograft (Bio-Oss) 
-AUT (misc)+SYN: FHA (C Graft) 
- 97 4-9 None 
15 Molly 2008 $ ESP 36 
-XEN (Bio-Oss) 
-SYN: PLG (Fisiograft) 
-SYN: HA (Biocoral) 
e-PTFE membrane NR 6 
Commercial 
support 
16 Mordenfeld 2014 LRA 28 
-AUT (mandible) 10%+xenograft (Bio-
Oss) 90% 
-AUT (mandible) 60%+xenograft (Bio-
Oss) 40% 
Collagen membrane 71 8.1 
Material 
donation 
17 Raghoebar 2005 SL 10 
-AUT (iliac) 
-AUT (iliac)+PRP 
- 30 3 NR 
18 Rickert 2011 SL 24 
-XEN (Bio-Oss)+stem cells 
-AUT (mandible)+xenograft (Bio-Oss) 








-SYN: BCP (BoneCeramic) 





-XEN (Bio-Oss)+autograft 20% (misc) 




21 Szabo 2005 SL/LRA 40/10 
-AUT (iliac) 
-SYN: b-TCP (Cerasorb) 
- 80 6 NR 
22 Wagner 2012 % SL 64 
-AUT (jaws)+xenograft (Bio-Oss) 
-SYN: MBCP (Tricos) 
- NR 6 
Commercial 
support 
23 Wiltfang 2003 SL 45 
-SYN: b-TCP (Curasan)+PRP 
-SYN: b-TCP (Curasan) 
- NR 6 NR 
24 Xavier 2014 SL 30 
-ALL (FDBA) 
-AUT (ramus) 
Collagen membrane 80 6 NR 
 
Parallel trials 








- 20 6 
Commercial 
support 
26 Checci 2011 ESP 10 
-SYN: HA (Sintlife) 
-SYN: HA (Ostim) 
Collagen sponge 10 6 None 
27 Cordaro 2011 LRA 22 
-AUT (mandible) 
-AUT+xenograft (Bio-Oss) 
Collagen membrane 55 4 External grant 
20 
28 de Freitas 2013 LRA 24 
-AUT (mandible) 
-GF: rhBMP-2/ACS 








-AUT (maxilla) 50%+xenograft (Bio-Oss) 
50% 
-AUT (maxilla) 20%+xenograft (Bio-Oss) 
80% 
Collagen membrane NR 6 External grants 
30 Hermund 2012 SL 20 
-AUT (maxilla)+xenograft (Bio-Oss) 
-AUT (maxilla)+xenograft (Bio-
Oss)+bone cells 
Collagen membrane 39 4 
Commercial 
support 
31 Jun 2014 SL 32 
-AUT (extracted tooth) 
-XEN (Bio-Oss) 


















-AUT (mandible)+SYN: BCP 
(BoneCeramic) 
-AUT (mandible)+SYN: BCP (Cerasorb) 
- - - Internal 
34 Kurkcu 2012 SL 23 
-XEN (BonePlus-xs) 
-SYN: BCP (BoneCeramic) 







-SYN: BCP (BoneCeramic) 
Collagen membrane - - 
Material 
donation 
36 Meijndert 2005 # LRA 10 
-AUT (chin) 
-XEN (Bio-Oss) 
Collagen membrane NR 3-6 
Commercial 
support 
37 Meijndert 2008 # ESP 62 
-AUT (chin) 
-XEN (Bio-Oss) 
Collagen membrane NR 3-6 
Commercial 
support 
38 Piattelli 2002 ESP 24 
-AUT (upper/lower jaw) 
-XEN (Bio-Oss) 
- 24 3-6 External grant 
39 Pikdoken 2011 SL 24 
-AUT (sinus) 20%+xenograft (NuOss) 
80% 
-XEN (NuOss) 80% 
Collagen membrane NR 4 NR 
40 Tosta 2013 SL 30 
-AUT (maxilla) 
-SYN: BCP (BoneCeramic) 
Collagen membrane NR 9 Internal 
41 Wood 2012 ESP 33 
-ALL (DFDBA) 
-ALL (FDBA) 
Collagen membrane - - 
Material 
donation 
ADMA, acellular dermal matrix allograft; ALL, allograft; AUT, autograft; BC, bone cyst; BCP, biphasic calcium phosphate; b-TCP, beta-tricalcium phosphate; CS, 
calcium sulfate; DFDBA, demineralized freeze-dried bone allograft; e-PTFE, expanded polytetrafluoroethylene; ESP, extraction socket preservation; FHA, fluoro-
hydroxyapatite; GF, growth factor; HA, hydroxyapatite; LRA, lateral ridge augmentation; MBCP, microporous and macroporous biphasic calcium phosphate; mos, 
months; NR, not reported; PLG, Poly-Lactide-co-Glycolide polymer; PRP, platelet rich plasma; rhBMP-2/ACS, recombinant human bone morphogenetic protein-2 
delivered on an Absorbable Collagen Sponge; rhGDF-5/b-TCP, recombinant human growth/differentiation factor-5 coated onto a β-tricalciumphosphate; SYN, 
synthetic bone substitute; SL, sinus lift; VRA, vertical ridge augmentation; XEN, xenograft. 
21 




Bone outcome (follow-up) Outcome (follow-up) 
 Cluster trials    
1 Bettega 2009 - 
Bone height & density (NR mos) 
Histomorphometry (6 mos) 
 
Implant survival (12 mos post-op) 
2 Cordaro 2008 - Histomorphometry (6-8 mos) - 
3 Corinaldesi 2013 - 
Bone height (4 mos) 
Histomorphometry (4 mos) 
- 
4 Crespi 2009a $ - 
Bone height & density (3 mos) 
Histomorphometry (3 mos) 
- 
5 Crespi 2009b - 
Histomorphometry (5 mos) 
Gene expression profiling (5 mos) 
- 
6 Crespi 2011 $ - Histomorphometry (4 mos) - 
7 Felice 2008 - Bone height (4 mos) - 
8 Froum 2002 $ √ Histomorphometry (6-8 mos) - 
9 Froum 2004 $ √ Histomorphometry (6-8 mos) - 
10 Froum 2008 √ Histomorphometry (6-8 mos) - 
11 Garlini 2014 √ Histomorphometry (6-8 mos) - 
12 Gholami 2012 - 
Bone width (6-8 mos) 
Histomorphometry (6-8 mos) 
- 
13 Kotsakis 2014 $ - Bone width & height (5 mos) 
Implant primary stability (NR mos) 
Implant success (20 mos post-op) 
14 Lee 2008 √ Histomorphometry (4-9 mos) - 
15 Molly 2008 $ - Histomorphometry (6 mos) Insertion torque and mobility of the implants (NR mos) 
16 Mordenfeld 2014 - 
Bone width (7.5 mos) 
Histomorphometry (8.1 mos) 
Implant failure (11.4 mos post-op) 
17 Raghoebar 2005 - 
Bone density (3 mos) 
Histomorphometry (3 mos) 
Implant failure (20.2 mos post-op) 
Implant compications (20.2 mos post-op) 
18 Rickert 2011 √ Histomorphometry (3.4 mos) Implant failure (3 mos post-op) 
19 Schmitt 2013 - 
Bone height (NR mos) 
Histomorphometry (5 mos) 
- 
20 Shirmohammadi 2014 √ 
Histomorphometry (5 mos) 
Bone height and density (5 mos)  
21 Szabo 2005 √ Histomorphometry (6 mos) Implant failure (6 mos post-op) 
22 Wagner 2012 % - Histomorphometry (6 mos) Implant stability (12 mos post-op) 
23 Wiltfang 2003 - Histomorphometry (6 mos) - 
24 Xavier 2014 √ Histomorphometry (6 mos) Implant failure (6 mos post-op) 
 
Parallel trials 
   
25 Calasans-Maia 2013 √ Histomorphometry (6 mos) - 
26 Checci 2011 - Histomorphometry (6 mos) - 
27 Cordaro 2011 - Bone width (24 mos after imp loading) - 
28 de Freitas 2013 - Bone width (6 mos) Implant success (6 mos post-op) 
29 Galindo-Moreno 2011 - Histomorphometry (6 mos) - 
30 Hermund 2012 - 
Bone height (4 mos) 
Histomorphometry (4 mos) 
- 
31 Jun 2014 - 
Bone height & density (4 mos) 
Sinus membrane thickness (4 mos) 
Histomorphometry (4 mos) 
Implant primary stability(4 mos post-op) 
32 
Koch 2010; Stavropoulos 
2011 
- Histomorphometry (3-4 mos) - 
33 Kuhl 2012; Kuhl 2013 - Bone density & volume (5 mos) - 
34 Kurkcu 2012 - Histomorphometry (6.5 mos) - 
35 
Mardas 2010; Mardas 2011; 
Patel 2013 
- 
Periodontal health of neighbouring teeth (8 mos) 
Bone width, height, and radioopacity (8 mos) 
Residual bone defects (NR mos) 
Resistance of bone to trephination (NR mos) 
Peri-implant bone height (12 mos post-loading) 
Implant failure (12 mos post-loading) 
36 Meijndert 2005 # - 
Histomorphometry (3-6 mos) 
Periodontal health (NR mos) 
- 
37 Meijndert 2008 # - 
Bone height (21-24 mos post-op) 
Periodontal health (21-24 mos post-op)  
38 Piattelli 2002 - Microvessel density (3-6 mos) - 
39 Pikdoken 2011 - 
Scintigraphic osteoblastic activity (4 mos) 
Histomorphometry (4 mos) 
- 
40 Tosta 2013 - Histomorphometry (9 mos) Implant failure (12 mos post-op) 
41 Wood 2012 - 
Histomorphometry (6-7 mos) 
Bone width and height 
- 
mos, monts; NR, not reported. 
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Appendix 7. Details of the risk of bias assessment for each of the 41 included trials in the systematic review. 





Blinding of outcome 
assessors 
Incomplete outcome data Selective outcome reporting Other sources of bias 
1 Bettega 2009 
(+) - "The iliac crest graft was 
then harvested, and the 
destination for the two 
techniques (traditional versus 
APC) was chosen through a 
two-element randomization 
table" 
(?) - no mention. 
(+) - blinding of the 
operator not possible; 
outcome assessment 
safeguarded. 
(+) - "All radiological 
images were read 
blindly by a 
radiologist…..Histologi
c bone assessment was 
performed blindly by 
the histologist." 
(+) - No drop-outs or patient 
losses are reported. 
(?) - It is difficult to judge 
whether selective reporting is a 
problem, as no protocol exists. 
(?) - residual bias 




(+) - unclear randomization; 
judged that the risk of bias 
could be classified as low: “The 
volunteer subjects were 
randomly assigned to the tests 
groups using an envelope 
system distribution provided 
by the principal investigator.” 
(+) - same as 
sequence generation. 
(+) - blinding of the 
operator not possible; 
outcome assessment 
safeguarded. 
(+) - “…, which were 
assessed by a single 
observer blinded to 
the clinical data”. 
(+) - No drop-outs or patient 
losses are reported. 
(?) - It is difficult to judge 
whether selective reporting is a 
problem, as no protocol exists. 
(+) - smoking and 
systemic diseases 
covered from the 
exclusion criteria. 
3 Checci 2011 
(?) - "At the time of extraction, 
the patients were randomly 
assigned to the test group (T) 
or the control group (C)." 
(?) - no mention. 
(+) - blinding of the 
operator not possible; 
outcome assessment 
safeguarded. 




using a light polarized 
microscope (Nikon 
Eclipse E800M, Tokyo, 
Japan),.." 
(+) - No drop-outs or patient 
losses are reported. 
(?) - It is difficult to judge 
whether selective reporting is a 
problem, as no protocol exists. 
(+) - smoking and 
systemic diseases 
covered from the 
exclusion criteria. 
4 Cordaro 2008 
(?) - randomization unclear 
(see allocation concealment). 
(+) - probably 
adequate: "The 
randomization 
envelope was opened 
and the patient could 
be allocated to either 
the test or control 
group only after 
completion of the 
elevation of the sinus 
membrane; in cases 




randomized to either 
the test or control 
group." 
(?) - blinding of the 
operator not possible; 
outcome assessment 
unclear. 
(?) - no mention. 
(-) - Variation in the number of 
available samples between 
groups without accounting for 
it in the results: "Measurable 
specimens were available from 
14 out of 25 sinuses for the 
test group (56% of the sites) 
and in 18 out of 23 sinuses in 
the control group (81.8% of 
the sites). 
(?) - It is difficult to judge 
whether selective reporting is a 
problem, as no protocol exists. 
(-) - clustered 
measurements 
treated correctly, but 
effect of smoking not 
addressed. 
5 Cordaro 2011 
(+) - "Randomization 
envelopes were generated by 
an independent statistician 
with the blocks method and 
kept by an administrative 
employee not involved in the 
study." 
(+) - allocation 
concealment 
adequate (same as 
sequence 
generation). 
(?) - blinding of the 
operator not possible; 
outcome assessment 
unclear. 
(?) - no mention. 
(+) - No drop-outs or patient 
losses are reported. 
(?) - It is difficult to judge 
whether selective reporting is a 
problem, as no protocol exists. 
(-) - smoking not 
taken into account, 






(?) - randomization unclear: 
"After the sinus membrane had 
been dissected and raised, 
block randomisation was used 
to designate a test side and a 
control side for each patient." 
(?) - no mention. 
(?) - blinding of the 
operator not possible; 
outcome assessment 
unclear. 
(?) - no mention. 
(+) - No drop-outs or patient 
losses are reported. 
(?) - It is difficult to judge 
whether selective reporting is a 
problem, as no protocol exists. 
(-) - raw data are 
given for each patient, 
but smoking among 
patients not reported. 
7 Crespi 2009a 
(-) - quasi-randomization 
(right/left mouth side): 
"Fifteen sockets, all on the 
right side of the mouth, 
received MHA (Ca10-
xMgx(PO4)6(OH)2) in granular 
form (SintLife, Finceramica) 
(MHA group); 15 sockets on 
the left side received xenogenic 
corticocancellous porcine bone 
(Tecnoss) (PB group); and 15 
unfilled random sockets were 
considered as control (C) 
group." 
(?) - no mention. 
(+) - blinding of the 
operator not possible; 
outcome assessment 
safeguarded. 
(+) - "A masked 
examinermeasured the 
bone level changes 
3months after the 
tooth extractions (Fig. 
2)." 
(+) - No drop-outs or patient 
losses are reported. 
(?) - It is difficult to judge 
whether selective reporting is a 
problem, as no protocol exists. 
(+) - raw data are 
given for each patient 
(smoking and 
systemic diseases 
covered from the 
exclusion criteria). 
8 Crespi 2009b 
(?) - randomization unclear: 
"According to the split-mouth 
design, all patients received 
autologous bone particles 
harvested from the ascending 
ramus of the mandible22,23 in 
a randomly assigned maxillary 
sinus" 
(?) - no mention. 
(?) - blinding of the 
operator not possible; 
outcome assessment 
unclear. 
(?) - no mention. 
(+) - No drop-outs or patient 
losses are reported. 
(-) - It is difficult to judge 
whether selective reporting is a 
problem, as no protocol exists. 
Data not adequately reported 
to allow processing. 
(-) - effect of smoking 
was not taken into 
account and no raw 
data reported. 
9 Crespi 2011 
(-) - quasi-randomization 
(right/left mouth side): "Split-
mouth treatment was 
performed: 15 sockets in the 
right side of the jaw received 
MHA (Ca10-
xMgx[PO4]6[OH]2) available in 
granule form,† 15 sockets in 
the left side received CS,‡ and 
15 unfilled random sockets 
were considered the control 
(C) group" 
(?) - no mention. 
(?) - blinding of the 
operator not possible; 
outcome assessment 
unclear. 
(?) - no mention. 
(+) - No drop-outs or patient 
losses are reported. 
(?) - It is difficult to judge 
whether selective reporting is a 
problem, as no protocol exists. 
(-) - clustered 
measurements 
treated as 
independent and no 




(+) - "Twenty-four small paper 
cards were consecutively 
marked as test (n = 12) or 
control (n = 12), folded and 
placed in a dark container for 
allocation concealment." 
(+) - "An assistant 
not involved in the 
study was then asked 
to draw one paper 
from the container." 
(+) - blinding of the 
operator not possible; 
outcome assessment 
safeguarded. 
(+) - "Radiographic 
recordings were 
performed by a 
masked examiner 
(RSN)." 
(+) - No drop-outs or patient 
losses are reported. 
(?) - It is difficult to judge 
whether selective reporting is a 
problem, as no protocol exists. 
(+) - smoking and 
systemic diseases 
covered from the 
exclusion criteria. 
11 Felice 2008 
(+) - "A computer-generated 
restricted randomisation list 
was created by an office of the 
S. Orsola-Malpighi hospital. 
None of the investigators were 
aware of the randomisation 
sequence." 
(+) - "The 
randomised codes 





(+) - blinding of the 
operator not possible; 
outcome assessment 
safeguarded. 
(+) - "Two dentists (Dr 
Fabio Rossi and Dr 
Gerardo Pellegrino) 
not involved in the 
treatment of the 
patients made all the 
clinical and 
(+) - "...no dropout, exclusion 
or deviation from the protocol 
occurred up to the insertion of 
the final prosthesis." 
(+) - "...no dropout, exclusion or 
deviation from the protocol 
occurred up to the insertion of 
the final prosthesis." 
(-) - clustered 
measurements 
treated correctly with 
paired t-tests, but 








knowledge of group 
allocation, therefore, 
outcome assessors 
were blind to these 
assessments. A 
biostatistician with 
expertise in dentistry 
analysed the data, 
without knowing the 
group codes." 
12 Froum 2002 
(+) - assumed to be adequate: 
"Treatment selection was then 
made randomly from sealed 
envelopes prepared by a 
statistician." 
(+) - assumed to be 
adequate (same as 
sequence 
generation). 
(+) - blinding of the 
operator not possible; 
outcome assessment 
safeguarded. 
(+) - "...measurements 
were performed by an 
investigator who had 
no knowledge of the 
treatment rendered." 
(+) - No drop-outs or patient 
losses are reported. 
(?) - It is difficult to judge 
whether selective reporting is a 
problem, as no protocol exists. 
(+) - raw data are 
given for each patient 
including patient's 
gender (smoking and 
systemic diseases 
covered from the 
exclusion criteria). 
13 Froum 2004 
(+) - assumed to be adequate: 
"Treatment selection was then 
made randomly from sealed 
envelopes prepared by a 
statistician." 
(+) - assumed to be 
adequate (same as 
sequence 
generation). 
(+) - blinding of the 
operator not possible; 
outcome assessment 
safeguarded. 




performed by an 
investigator who had 
no knowledge of the 
treatment rendered." 
(+) - No drop-outs or patient 
losses are reported. 
(?) - It is difficult to judge 
whether selective reporting is a 
problem, as no protocol exists. 
(+) - raw data are 






covered from the 
exclusion criteria). 
14 Froum 2008 
(+) - The sinus membrane was 
then elevated across the floor 
and up the medial wall. BCP 
was placed in one subantral 
compartment and ABBM was 
placed in the contralateral 
subantral compartment, as 
determined by a computer-
generated randomized code." 
(?) - no mention. 
(?) - blinding of the 
operator not possible; 
outcome assessment 
unclear. 
(?) - no mention. 
(+) - dropout judged not to be 
substantial or related to the 
interventions: "One withdrew 
for financial reasons, one 
because of an inability to 
obtain cores within the study 
time protocol, and one because 
of an infection that required 
re-entry and debridement 
prior to the time required for 
core harvesting." 
(?) - It is difficult to judge 
whether selective reporting is a 
problem, as no protocol exists. 
(-) - raw data are 
given for each patient, 
but smoking among 




(?) - "Patients were randomly 
assigned to the two groups 
(n=14 each).. 
(?) - no mention. 
(+) - blinding of the 
operator not possible; 
outcome assessment 
safeguarded. 





conducted by an 
experienced, masked 
examiner (F.O.)." 
(+) - No drop-outs or patient 
losses are reported. 
(?) - It is difficult to judge 
whether selective reporting is a 
problem, as no protocol exists. 
(-) - smoking not 
taken into account, 
and no raw data 
given. 
16 Garlini 2014 
(?) - “A randomized clinical 
study with a split-mouth 
design” 
(?) - no mention. 
(?) - blinding of the 
operator not possible; 
outcome assessment 
unclear. 
(?) - no mention. 
(+) - No drop-outs or patient 
losses are reported. 
(?) - It is difficult to judge 
whether selective reporting is a 
problem, as no protocol exists. 
(-) - effect of smoking 
was not taken into 
account and smoking 
status not reported in 
raw data. 
25 
17 Gholami 2012 
(+) - “Fifteen symmetrical pairs 
were randomly selected, using 
a random number table, as one 
side of the mouth in each 
patient..” 
(?) - no mention. 
(+) - blinding of the 
operator not possible; 
outcome assessment 
safeguarded. 
(+) - The sections were 
analyzed by an 
examiner masked to 
the type of treatment.” 
(+) - 2 missing patients; due to 
the trial’s design, losses are 
balanced. 
(?) - It is difficult to judge 
whether selective reporting is a 
problem, as no protocol exists. 
(-) - smoking not 
taken into account, 
and no raw data 
given. 
18 Hermund 2012 
(+) - "and then the patients 
were randomly assigned to a 
control (n = 10) or test group 
(n = 10) using a blinded draw 
from a bag containing 20 
identical pieces of paper with 
the group name printed on 
them" 
(?) - no mention. 
(+) - blinding of the 
operator not possible; 
outcome assessment 
safeguarded. 
(+) - "A single, 
previously calibrated 
examiner (NUH), who 




(+) - minor missing samples 
from some implant 
positions/judged to be 
insignificant. 
(?) - It is difficult to judge 
whether selective reporting is a 
problem, as no protocol exists. 
(-) - smoking not 
taken into account, 
and no raw data 
given. 
19 Jun 2014 
(+) - “The allocation of the 
participants was done by 
random sequence generator.” 
(?) - no mention. 
(+) - blinding of the 
operator not possible; 
outcome assessment 
safeguarded. 
(+) - “This 
measurement was 
performed by one oral 
and maxillofacial 
surgeon who does not 
know the control/ 
experimental group.” 
(+) - equal number of drop-out 
for the two groups; judged to 
be insignificant. 
(?) - It is difficult to judge 
whether selective reporting is a 
problem, as no protocol exists. 
(-) - smoking not 
taken into account, 






(+) - "For sinus floor 
augmentation, three treatment 
groups were randomized 
according to a computer-
generated list." 
(?) - no mention. 
(+) - blinding of the 
operator not possible; 
outcome assessment 
safeguarded. 
(+) - "Two experienced 
evaluators (A. S. and H. 
T.), blinded with 




(+) - only one patient excluded; 
judged insignificant. 
(?) - It is difficult to judge 
whether selective reporting is a 
problem, as no protocol exists. 
(-) - smoking not 
taken into account, 
and membrane used 
in some cases; no raw 
data given. 
21 Kotsakis 2014 
(?) - randomization not clear, 
as experimental groups were 
twice as large than the control 
group and no description is 
given: "were allocated to either 
one of the test groups or the 
control group according to a 
randomization list." 
(?) - no mention. 
(+) - blinding of the 
operator not possible; 
outcome assessment 
safeguarded. 






months by the same 
blinded examiner who 
had performed the 
baseline 
measurements and 
was not involved in 
the surgical treatment" 
(+) - No drop-outs or patient 
losses are reported. 
(?) - It is difficult to judge 
whether selective reporting is a 
problem, as no protocol exists. 
(-) - clustered 
measurements 
treated as 
independent and no 




(+) - "Before surgical 
treatment, patients were 
randomly enrolled in one of 
three treatment groups:" 
(?) - no mention. 
(?) - blinding of the 
operator not possible; 
outcome assessment 
unclear. 
(?) - no mention. 
(+) - excluded patients evenly 
distributed among groups. 
(?) - It is difficult to judge 
whether selective reporting is a 
problem, as no protocol exists. 
(+) - smoking and 
systemic diseases 
covered from the 
exclusion criteria. 
23 Kurkcu 2012 
(-) - semi-randomization: "The 
patients were randomly 
allocated to 1 of 2 groups 
according to admission order." 
(?) - no mention. 
(?) - blinding of the 
operator not possible; 
outcome assessment 
unclear. 
(?) - no mention. 
(+) - excluded patients evenly 
distributed among groups. 
(?) - It is difficult to judge 
whether selective reporting is a 
problem, as no protocol exists. 
(-) - smoking not 
taken into account, 
and no raw data 
given. 
24 Lee 2008 
(?) - randomization unclear: 
"Randomization schedules 
were designed to provide a 
balanced distribution of graft 
material in each patient." 
(?) - no mention. 
(?) - blinding of the 
operator not possible; 
outcome assessment 
unclear. 
(?) - no mention. 
(-) - Selective random 
reporting of samples, leading 
to unequal distribution among 
groups: "Ten randomly 
selected bone core samples 
(?) - It is difficult to judge 
whether selective reporting is a 
problem, as no protocol exists. 
(-) - raw data are 
given for each patient, 
but smoking among 







(+) - "The subjects were 
randomly assigned to the test 
or the control group by a 
computergenerated table. A 
balanced randomly permuted 
block approach was used to 
prepare the randomization 
tables in order to avoid 
unequal balance between the 
two treatments. The subjects 
were randomized according to 
smoking habits." 
(+) - "After 




envelope was opened 
and the assigned 
treatment (test or 
control) was 
revealed to the 
surgeon." 
(+) - blinding of the 
operator not possible; 
outcome assessment 
safeguarded. 




made by a single, 
blinded previously 
calibrated examiner 
other than the 
surgeon, who was also 
not aware of the 
treatment assignment 
(test or control)." 
(+) - One patient exclluded 
after randomization and this 
was judged to be insignificant: 
"Two patients were excluded 
before randomization due to 
complete loss of the buccal 
osseous plate following 
extraction. One patient 
withdrew from the study 
before randomization and 
another who had been 
assigned to the test group quit 
the study before implant 
placement." 
(?) - It is difficult to judge 
whether selective reporting is a 
problem, as no protocol exists. 




26 Meijndert 2005 
(+) - "A computer software 
program randomly placed the 
participating patients into 
these groups." 
(?) - no mention. 
(?) - blinding of the 
operator not possible; 
outcome assessment 
unclear. 
(?) - no mention. 
(+) - No drop-outs or patient 
losses are reported. 
(?) - It is difficult to judge 
whether selective reporting is a 
problem, as no protocol exists. 
(+) - smoking and 
systemic diseases 
covered from the 
exclusion criteria. 
27 Meijndert 2008 
(+) - "A computer software 
program randomly placed the 
participating patients into one 
of these groups, using a 
balancing procedure aimed at 
an equal distribution of 
patients over the treatment 
groups regarding variables 
that may interfere with the 
outcome of the study" 
(?) - no mention. 
(?) - blinding of the 
operator not possible; 
outcome assessment 
unclear. 
(?) - no mention. 
(+) - 2 samples were 
excluded/judged to be 
insignificant. 
(?) - It is difficult to judge 
whether selective reporting is a 
problem, as no protocol exists. 
(+) - smoking and 
systemic diseases 
covered from the 
exclusion criteria. 
28 Molly 2008 
(-) - "the experimental 
treatments, consisting of at 
least two bone biomaterials 
and one control, were applied 
randomly in each subject": 
randomization unclear, but the 
paper is titled "Case series". 
(?) - no mention. 
(?) - blinding of the 
operator not possible; 
outcome assessment 
unclear. 
(?) - no mention. 
(+) - No drop-outs or patient 
losses are reported. 
(?) - It is difficult to judge 
whether selective reporting is a 
problem, as no protocol exists. 
(-) - clustered 
measurements 
treated correctly with 
linear mixed 
modelling, but not 
clearly reported and 




(+) - probably adequate: "The 
allocation sequence was 
computer-generated by a 
statistician at Gavleborg 
County Hospital, Sweden, and 
concealed in envelopes until 
randomization." 
(+) - probably 
adequate (same as 
sequence 
generation). 
(?) - blinding of the 
operator not possible; 
outcome assessment 
unclear. 
(?) - no mention. 
(+) - "All 28 specimens, 14 
from each mixture and grafted 
site, could be used for 
histomorphometry, and the 
grafted tissue was easily 
distinguished from the 
residual bone." 
(?) - It is difficult to judge 
whether selective reporting is a 
problem, as the trial was not 
registered and no protocol 
exists. 
(+) - clustered 
measurements 




covered from the 
exclusion criteria). 
30 Piattelli 2002 
(?) - "The defects were filled in 
a random manner with 
autologous bone harvested 
with a trephine from adjacent 
areas and ground in a bone 
(?) - no mention. 
(?) - blinding of the 
operator not possible; 
outcome assessment 
unclear. 
(?) - no mention. 
(+) - No drop-outs or patient 
losses are reported. 
(?) - It is difficult to judge 
whether selective reporting is a 
problem, as no protocol exists. 
(?) - no mention of 




mill, or with Bio-Oss." 
31 Pikdoken 2011 
(?) - randomization unclear: "A 
balanced randomization was 
performed by a clinician who 
intended to distribute the 
patients into 2 groups 
including equal numbers of 
patients." 
(?) - no mention. 
(+) - blinding of the 
operator not possible; 
outcome assessment 
safeguarded. 
(+) - "Histologic and 
histomorphometric 
assessments were 
carried out by 2 
pathologists (Z.K. and 
E.B.) who were not 
informed about the 
treatment modalities." 
(+) - No drop-outs or patient 
losses are reported. 
(?) - It is difficult to judge 
whether selective reporting is a 
problem, as no protocol exists. 
(+) - smoking and 
systemic diseases 





(?) - randomization unclear: 
"Randomly, one side was 
reconstructed with autologous 
bone mixed with PRP gel and 
one side with autologous bone 
only." 
(?) - no mention. 
(+) - blinding of the 
operator not possible; 
outcome assessment 
safeguarded. 
(+) - "The 
investigators were 
blinded for both the 
clinical and laboratory 
investigations with 
regard to the PRP-
treated side." 
(+) - No drop-outs or patient 
losses are reported. 
(?) - It is difficult to judge 
whether selective reporting is a 
problem, as no protocol exists. 
(-) - raw data are 
given for each patient, 
but no mention of 
smoking as an 
inclusion/exclusion 
criterion. 
33 Rickert 2011 
(+) - randomization somewhat 
unclear, but judged to be 
adequate: "Randomly, 
performed by envelopes, on 
one side the augmentation 
procedure was performed with 
bovine bone mineral (BioOsss, 
Geistlich Biomaterials, 
Wolhusen, Switzerland) 
seeded with MSCs harvested" 
(+) - no mention if 




judged to be 
adequate (same as 
sequence 
generation). 
(+) - blinding of the 
operator not possible; 
outcome assessment 
safeguarded. 
(+) - "The histologists 





(+) - One patient excluded, but 
reasoning adequate. 
(?) - It is difficult to judge 
whether selective reporting is a 
problem, as no protocol exists. 
(+) - raw data are 
given for each patient 
(smoking and 
systemic diseases 
covered from the 
exclusion criteria). 
34 Schmitt 2013 
(?) - randomization unclear: 
"The test groups (ABB, BCP, 
and MCBA) and the control 
group (AB) were allocated to 
the participant’s sinus under 
randomized conditions." 
(?) - no mention. 
(?) - blinding of the 
operator not possible; 
outcome assessment 
unclear. 
(?) - no mention. 
(+) - only half of the harvested 
samples were analyzed. 
However, as the distribution 
among the interventions was 
relatively well-balanced, it was 
assumed to have no effect on 
the results (although the 
authors didn't formally assess 
this): "Fifty-three bone 
biopsies were generated from 
the later implant site; 41 
samples were lost during 
removal or the location of the 
implant was peripheral to the 
augmented maxillary sinus." 
(?) - It is difficult to judge 
whether selective reporting is a 
problem, as no protocol exists. 




smoking not taken 
into account, and no 




(?) - "After elevation of the 
sinusmembrane on a random 
basis, on one 
side,Ostim(Heraeus Kulzer 
GmbH and 63450 Hanau, 
Germany) with 20% 
autogenous bone graft was 
used and on the other side Bio-
Oss (Geistlich Pharma AG and 
6110 Wolhusen, Switzerland) 
(?) - no mention. 
(+) - blinding of the 
operator not possible; 
outcome assessment 
safeguarded. 
(+) - "The histologist 
(LR) was blinded to 
the type of the bone 
grafts used in sinus 
augmentation." 
(+) - One drop-outs or patient 
losses reported. Due to the 
split-mouth nature, 
observations are balanced. 
(+) - No serious discrepancies 






(+) - raw data are 
given for each patient 
(smoking and 
systemic diseases 
covered from the 
exclusion criteria). 
28 
with 20% autogenous bone 
graft was applied." 
36 Szabo 2005 
(+) - "The choice of sides was 
randomized using the coin-toss 
method." 
(?) - no mention. 
(?) - blinding of the 
operator not possible; 
outcome assessment 
unclear. 
(?) - no mention. 
(+) - No drop-outs or patient 
losses are reported. 
(?) - It is difficult to judge 
whether selective reporting is a 
problem, as no protocol exists. 
(-) - raw data are 
given for each patient 
(systemic diseases 
covered from the 
exclusion criteria). 
However, no mention 
of smoking as an 
inclusion/exclusion 
criterion. 
37 Tosta 2013 
(?) - "The space created was 
grafted – to allow the future 
placement of implants of 12-
mm in length – with either a 
synthetic particulate bone 
substitute (test group – 
biphasic calciumphosphate – 
Straumann BoneCeramic®, 
Institut Straumann AG), or 
with a particulate autogenous 
bone graft harvested 
intraorally from the tuberosity 
area (control group), 
depending on the 
randomization process." 
(?) - no mention. 
(?) - blinding of the 
operator not possible; 
outcome assessment 
unclear. 
(?) - no mention. 
(+) - No drop-outs or patient 
losses are reported. 
(?) - It is difficult to judge 
whether selective reporting is a 
problem, as no protocol exists. 
(+) - smoking and 
systemic diseases 
covered from the 
exclusion criteria. 
38 Wagner 2012 
(+) - somewhat unclear, but 
judged to be adequate: 
"Immediately prior to study 
treatment, the investigator 
opened a sealed randomization 
envelope containing the 
assignment of the MBCP-FS 
graft treatment to either the 
right or the left sinus." 
(+) - somewhat 
unclear, but judged 
to be adequate (same 
as sequence 
generation). 
(?) - blinding of the 
operator not possible; 
outcome assessment 
unclear. 
(?) - no mention. 
(+) - No drop-outs or patient 
losses are reported. 
(?) - It is difficult to judge 
whether selective reporting is a 
problem, as no protocol exists. 
(?) - no mention of 
smoking as an 
inclusion/exclusion 
criterion. 
39 Wiltfang 2003 
(?) - "One milliliter of PRP was 
administered in addition to the 
ceramic material in 17 sites in 
a randomized prospective 
study approved by the ethics 
commission of the University 
of Erlangen-Nuremberg 
(application no. 2075)." 
(?) - no mention. 
(?) - blinding of the 
operator not possible; 
outcome assessment 
unclear. 
(?) - no mention. 
(+) - No drop-outs or patient 
losses are reported. 
(-) - It is difficult to judge 
whether selective reporting is a 
problem, as no protocol exists. 
Data not adequately reported 
to allow processing. 
(?) - no mention of 
smoking as an 
inclusion/exclusion 
criterion. 
40 Wood 2012 
(+) - randomization somewhat 
unclear, but judged to be 
adequate: "Forty patients were 
enrolled, and each participant 
was assigned to one of the two 
(+) - allocation 
concealment 
somewhat unclear, 
but judged to be 
adequate (same as 
(?) - blinding of the 
operator not possible; 
outcome assessment 
unclear. 
(?) - no mention. 
(-) - Thirtytwo out of forty 
samples analyzed and 
distribution between 
experimenal groups not 
assessed. 
(?) - It is difficult to judge 
whether selective reporting is a 
problem, as no protocol exists. 
(+) - smokers not 
actively excluded, but 
no smokers were 
enrolled. 
29 
treatment groups at the time of 




41 Xavier 2014 
(+) - randomization somewhat 
unclear, but judged to be 
adequate: “The choice of 
whether the sinus (left or 
right) would contain the test 
substance (fresh frozen bone) 
or autologous bone was 
determined randomly, using a 
randomized table.” 
(?) - no mention. 
(?) - blinding of the 
operator not possible; 
outcome assessment 
unclear. 
(?) - no mention. 
(+) - No drop-outs or patient 
losses are reported. 
(?) - It is difficult to judge 
whether selective reporting is a 
problem, as no protocol exists. 
(+) - smoking and 
systemic diseases 
covered from the 
exclusion criteria. 







Crespi 2009 a 
Crespi 2009 b 
Crespi 2011 
































































































































































































































































































































A B C D E F G 
Appendix 8. Risk of bias of the 41 trials included in the systematic review. A, selection bias – random sequence; B, selection bias – allocation; C, 








0% 25% 50% 75% 100% 
Low risk of bias Unclear risk of bias High risk of bias 
Appenfix 9. Risk of bias summary across the 41 trials included in the systematic review. A, selection bias – random sequence; B, selection bias – 
allocation; C, performance bias; D, detection bias; E, attrition bias; F, reporting bias; G, other bias. 
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Appendix 10. Results of individual trials included in the systematic review, including all reported outcomes. Adjusted estimates stem from individual 
participant data and are controlled for patient, age, sex, and membrane (where applicable). 
Cluster trials – raw and adjusted estimates 
Info Factor MD SE 95% CI P value 
S: Crespi 2009a 
C: SintLife vs EasySet 
     
O1: %new bone      
Raw est. Graft type -5.02 1.84 -8.62,-1.42 0.006 
      
Adj. est. Graft type -5.02 1.84 -8.62,-1.42 0.006 
 Age -0.09 0.09 -0.27,0.09 0.310 
 Sex 1.10 2.17 -3.15,5.36 0.611 
O2: %residual graft      
Raw est. Graft type 6.32 1.41 3.56,9.08 <0.001 
      
Adj. est. Graft type 6.32 1.41 3.56,9.08 <0.001 
 Age -0.09 0.05 -0.19,0.01 0.071 
 Sex 0.84 1.20 -1.51,3.19 0.482 
O3: %connective tissue      
Raw est. Graft type -0.20 2.00 -4.12,3.72 0.920 
      
Adj. est. Graft type -0.20 2.00 -4.12,3.72 0.920 
 Age 0.10 0.08 -0.06,0.26 0.221 
 Sex 1.92 1.91 -1.81,5.65 0.313 
O4: bone height change      
Raw est. Graft type -2.02 0.17 -2.34,-1.69 <0.001 
      
Adj. est. Graft type -2.02 0.17 -2.34,-1.69 <0.001 
 Age -0.01 0.01 -0.03,0.00 0.128 
 Sex 0.20 0.20 -0.18,0.59 0.299 
      
S: Froum 2002 
C: Biogran vs ALL 
     
O1: %new bone      
Raw est. Graft type -23.28 6.85 -36.69,-9.86 0.001 
      
Adj. est. Graft type -25.33 5.99 -37.07,-13.58 <0.001 
 Age -0.58 0.32 -1.20,0.05 0.069 
 Sex 1.45 8.48 -15.17,18.08 0.864 
 Healing time 6.79 3.98 -1.01,14.59 0.088 
O2: %residual graft      
Raw est. Graft type 8.31 1.73 4.92,11.70 <0.001 
      
Adj. est. Graft type 9.57 1.62 6.40,12.75 <0.001 
 Age 0.07 0.07 -0.07,0.21 0.329 
 Sex -2.08 1.89 -5.79,1.62 0.270 
 Healing time -2.29 0.85 -3.95,-0.63 0.007 
O3: %connective tissue      
Raw est. Graft type 15.65 6.49 2.94,28.37 0.016 
      
Adj. est. Graft type 17.73 6.14 5.69,29.76 0.004 
 Age 0.50 0.33 -0.15,1.15 0.131 
 Sex -0.23 8.85 -17.59,17.12 0.979 
 Healing time -4.17 4.16 -12.33,3.98 0.316 
      
S: Froum 2004 
C: Osteograf R/LD vs Osteograf R/N300 
     
O1: %new bone      
Raw est. Graft type 2.46 7.70 -12.63,17.55 0.749 
      
Adj. est. Graft type 4.71 6.61 -8.25,17.68 0.476 
 Age -0.29 0.27 -0.82,0.25 0.290 
 Membrane -13.64 6.65 -26.68,-0.59 0.040 
 Healing time -3.34 4.65 -12.46,5.77 0.472 
O2: %residual graft      
Raw est. Graft type -5.81 5.01 -15.63,4.01 0.246 
      
Adj. est. Graft type -7.99 4.82 -17.43,1.46 0.097 
 Age 0.31 0.20 -0.09,0.70 0.128 
 Membrane 4.59 5.88 -6.93,16.12 0.435 
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 Healing time 2.83 3.45 -3.93,9.58 0.412 
O3: %connective tissue      
Raw est. Graft type 7.95 6.76 -5.29,21.19 0.239 
      
Adj. est. Graft type 7.97 6.85 -5.45,21.38 0.245 
 Age 0.23 0.29 -0.33,0.79 0.423 
 Membrane 10.12 8.22 -6.00,26.24 0.219 
 Healing time -1.38 4.93 -11.05,8.29 0.780 
      
S: Froum 2008 
C: BoneCeramic vs BioOss 
     
O1: %new bone      
Raw est. Graft type 6.08 7.08 -7.80,19.97 0.391 
      
Adj. est. Graft type 4.30 7.28 -9.97,18.57 0.555 
 Healing time 5.66 4.75 -3.64,14.97 0.233 
O2: %residual graft      
Raw est. Graft type 1.88 5.53 -8.96,12.73 0.734 
      
Adj. est. Graft type 3.92 5.35 -6.57,14.41 0.464 
 Healing time -5.99 3.15 -12.16,0.18 0.057 
O3: %connective tissue      
Raw est. Graft type -8.11 5.04 -18.00,1.77 0.108 
      
Adj. est. Graft type -8.22 5.15 -18.31,1.88 0.111 
 Healing time 0.26 3.11 -5.85,6.36 0.935 
      
S: Garlini 2014 
C: Algipore vs BioOss 
     
O1: %new bone      
Raw est. Graft type -11.18 6.13 -23.20,0.83 0.068 
      
Adj. est. Graft type -10.82 6.59 -23.74,2.10 0.101 
 Age 0.51 0.22 0.08,0.94 0.021 
 Sex 13.32 5.52 2.51,24.12 0.016 
 Healing time -1.82 4.55 -10.73,7.10 0.690 
O2: %residual graft      
Raw est. Graft type 20.56 7.58 5.71,35.42 0.007 
      
Adj. est. Graft type 23.34 3.23 17.01,29.68 <0.001 
 Age -0.82 0.37 -1.55,-0.10 0.027 
 Sex -9.81 8.95 -27.35,7.72 0.273 
 Healing time -13.89 3.12 -20.00,-7.78 <0.001 
O3: %connective tissue      
Raw est. Graft type -9.38 5.71 -20.57,1.81 0.100 
      
Adj. est. Graft type -9.25 5.95 -20.90,2.40 0.120 
 Age -0.07 0.09 -0.24,0.11 0.451 
 Sex 7.02 2.26 2.59,11.45 0.002 
 Healing time -0.68 2.20 -5.00,3.62 0.758 
      
S: Kotsakis 2014 
C: NovaBone vs BioOss 
     
O1: absolute horizontal bone change      
Raw est. Graft type -0.13 0.20 -0.52,0.27 0.530 
      
O2: absolute vertical bone change      
Raw est. Graft type -0.06 0.11 -0.27,0.15 0.562 
      
S: Rickert 2011 
C: BioOss+stem cells vs BioOss+AUT 
     
O1: %new bone      
Raw est. Graft type 5.78 1.83 2.19,9.37 0.002 
      
O2: %residual graft      
Raw est. Graft type 3.18 3.51 -3.69,10.06 0.364 
      
O3: %connective tissue      
Raw est. Graft type -1.66 2.49 -6.54,3.21 0.503 
      
32 
S: Shirmohammadi 2014 
C: Ostim vs BioOss 
     
O1: %new bone      
Raw est. Graft type 6.19 1.48 3.29,9.09 <0.001 
      
O2: %residual graft      
Raw est. Graft type -9.96 2.32 -14.51,-5.41 <0.001 
      
O3: %connective tissue      
Raw est. Graft type 3.78 3.25 -2.59,10.14 0.245 
      
O4: bone density      
Raw est. Graft type 22.00 8.00 6.32,37.68 0.006 
      
O5: bone height      
Raw est. Graft type 0.52 0.35 -0.17,1.21 0.138 
      
S: SzabO2005 
C: Cerasorb vs AUT 
     
O1: %new bone      
Raw est. Graft type -1.88 1.94 -5.69,1.93 0.333 
      
O2: %residual graft      
Raw est. Graft type 5.50 1.01 3.52,7.48 <0.001 
      
O3: %connective tissue      
Raw est. Graft type -3.61 1.91 -7.36,0.13 0.059 
      
S: Xavier 2014 
C: AUT vs ALL 
     
O1: %new bone      
Raw est. Graft type -0.01 0.48 -0.95,0.93 0.981 
      
O2: %residual graft      
Raw est. Graft type -1.16 2.57 -6.20,3.89 0.653 
      
O3: %connective tissue      
Raw est. Graft type 1.17 2.59 -3.92,6.25 0.653 
Parallel trials – Raw estimates – MD (unless stated otherwise) 
S: Calasans-Maia 2013 
C: Osseus vs BioOss 
     
 Graft type     
O1: %new bone  14.4 7.49 -0.28,29.08 0.055 
O2: %residual graft  -11.9 5.70 -23.07,-0.73 0.037 
O3: %connective tissue  -17.6 5.27 -27.93,-7.27 0.001 
O4: bone width change  -0.10 0.06 -0.23,0.03 0.130 
      
S: Checci 2011 
C: SintLife vs Ostim 
     
 Graft type     
O1: %new bone  5.00 15.92 -26.21,36.21 0.754 
O2: %residual graft  -6.00 4.43 -14.68,2.68 0.175 
O3: %connective tissue  -4.00 4.60 -13.02,5.02 0.385 
      
S: CordarO2011 
C: AUT vs BioOss+AUT 
     
 Graft type     
O1: final bone gain  0.26 0.53 -0.77,1.29 0.622 
O2: final bone resorption  -0.64 0.55 -1.72,0.44 0.243 
      
S: de Freitas 2013 
C: rhBMP-2/ACS vs AUT 
     
 Graft type     
O1: clin. bone width  -0.50 0.48 -1.44,0.44 0.298 
O2: rad. bone width 2mm from crest  1.00 0.33 0.36,1.65 0.002 
O3: rad. bone width 6mm from crest  0.00 0.35 -0.68,0.68 1.00 
O4: rad. bone width 10mm from crest  -0.100 0.41 -0.90,0.70 0.807 
O5: implant failure (primary stability)  RR:6.56 1.04 0.89,50.23 0.070 
      
S: Galindo-MorenO2011      
33 
C: BioOss+AUT(8/2) vs BioOss+AUT (5/5) 
 Graft type     
O1: %vital bone  1.38 5.30 -9.02,11.78 0.795 
O2: %residual graft  11.39 6.30 -0.95,23.73 0.070 
O3: %non-mineralized tissue  -12.88 5.61 -23.87,-1.89 0.022 
O4: osteoblast cells  -84.84 61.10 -204.59,34.91 0.165 
O5: osteoclast cells  -55.97 47.14 -148.37,36.43 0.235 
O6: osteocytes  -412.77 164.82 -735.80,-89.74 0.012 
O7: osteoid lines  -9.04 3.36 -15.62,-2.46 0.007 
      
S: Hermund 2012 
C: BioOss+autograft+bone cells vs BioOss+autograft 
     
 Graft type     
O1: bone density at position 1  5.00 8.17 -11.01,21.01 0.540 
O2: bone density at position 2  5.00 7.43 -9.56,19.56 0.501 
O3: bone density at position 3  -11.00 8.42 -27.51,5.51 0.192 
      
S: Jun 2014 
C: BioOss vs AUT 
     
 Graft type     
O1: %new bone  -4.58 4.17 -12.76,3.60 0.272 
O2: %residual graft  2.12 4.91 -7.51,11.75 0.666 
O3: %connective tissue  2.45 6.69 -10.66,15.56 0.714 
O4: osteoid thickness  -4.77 1.72 -8.14,-1.40 0.006 
O5: new bone radioopacity (HU)  -51.23 38.36 -126.42,23.96 0.182 
O6: new bone mineral density  -0.02 0.01 -0.03,-0.01 0.005 
O7: trabecular thickness  -0.01 0.01 -0.02,0.00 0.087 
O8: (micro-CT) %new bone/total bone  -4.76 3.90 -12.41,2.89 0.222 
      
Koch 2010+following 
C: rhGDF-5+Ceraver Osteal vs AUT+Ceraver Osteal 
     
 Graft type     
O1: %new bone  -3.80 7.49 -18.48,10.88 0.612 
O2: %bone marrow  12.10 7.58 -2.76,26.96 0.111 
O3: %dense fibrous tissue  1.60 11.47 -20.89,24.09 0.889 
O4: %residual graft  -9.90 4.37 -18.47,-1.34 0.023 
      
Kuhl 2012; Kuhl 2013 
C: AUT vs Cerasorb or BoneCeramic 
     
      
O1: bone density Cerasorb -23.00 37.01 -95.55,49.55 0.534 
 BoneCeramic -20.00 32.29 -83.29,43.29 0.536 
      
O2: bone volume Cerasorb -4.10 3.80 -11.54,3.34 0.280 
 BoneCeramic -0.70 4.29 -9.11,7.71 0.870 
      
C: Cerasorb vs BoneCeramic      
O3: %residual graft  0.10 2.44 -4.69,4.89 0.967 
      
S: Kurkcu 2012 
C: BoneCeramic vs BonePlus-xs 
     
 Graft type     
O1: %new bone  9.04 1.32 6.46,11.62 <0.001 
O2: %residual graft  -2.17 1.93 -5.95,1.61 0.261 
O3: %connective tissue  -6.87 2.13 -11.04,-2.70 0.001 
      
Mardas 2010+following 
C: BoneCeramic vs BioOss 
     
 Graft type     
O1: change in probing depth  0.30 0.16 -0.01,0.61 0.056 
O2: change in gingival recession  -0.10 0.06 -0.22,0.02 0.107 
O3: change in bone width  1.00 0.39 0.23,1.77 0.011 
O4: change in Bbw  -0.30 0.28 -0.84,0.24 0.279 
O5: change in L/Pbw  -0.40 0.32 -1.02,0.22 0.206 
O6: change in Mbh  -0.60 0.34 -1.27,0.07 0.080 
O7: change in Dbh  0.00 0.40 -0.79,0.79 1.00 
O8: hard bone tissue after healing  RR:1.00 0.92 0.17,6.07 1.00 
O9: implant failure  RR:0.92 0.92 0.15,5.56 0.930 
O10: fenestrations around implants  RR:3.00 1.09 0.36,25.21 0.312 
O11: pristine defects around implants  RR:1.00 0.59 0.32,3.17 1.000 
34 
O12: dehiscence around imlpants  RR:0.86 0.86 0.40,1.86 0.696 
Various more specific bone height measurements omitted      
      
S: Meijnert 2005 
C: BioOss vs AUT 
     
 Graft type     
O1: %new bone  -40.10 8.28 -56.32,-23.88 <0.001 
O2: %connective tissue  -0.40 7.80 -15.68,14.88 0.959 
      
S: Meijnert 2008 
C: BioOss vs AUT 
     
 Graft type     
O1: bone mesial to implant  -0.03 0.19 -0.40,0.34 0.872 
O2: bone distal to implant  -0.03 0.14 -0.30,0.24 0.826 
O3: gingiva mesial to implant  0.11 0.12 -0.13,0.35 0.368 
O4: gingiva distal to implant  0.16 0.16 -0.15,0.47 0.264 
O5: gingiva buccal to implant  -0.21 0.19 -0.58,0.16 0.720 
Various measurement at the teeth adjacent to the grafted area 
omitted 
     
      
S: Piatelli 2002 
C: BioOss vs AUT 
     
 Graft type     
O1: microvessel density  -0.10 1.45 -2.94,2.74 0.945 
      
S: Pikdoken 2011 
C: BioOss+AUT (8/2) vs BioOss 
     
 Graft type     
O1: 99mTc-MDP uptake (scintigrafic activity)  0.33 0.40 -0.45,1.11 0.407 
O2: %new bone  1.54 0.99 -0.41,3.49 0.121 
O3: %residual graft  -2.55 2.95 -8.32,3.22 0.387 
O4: %connective tissue  1.18 2.60 -3.91,6.27 0.650 
      
S: Tosta 2013 
C: BoneCeramic vs AUT 
     
 Graft type     
O1: %new bone  -7.33 2.40 -12.04,-2.62 0.002 
O2: %connective tissue  -25.82 2.39 -30.51,-21.14 <0.001 
      
S: Wood 2012 
C: DFDBA vs FDBA 
     
 Graft type     
O1: %new bone  13.79 4.97 4.04,23.54 0.006 
O2: %residual graft  -16.54 5.33 -26.98,-6.10 0.002 
O3: %connective tissue  2.77 3.41 -3.91,9.45 0.416 
O4: bone height buccally  -0.20 0.41 -0.99,0.59 0.621 
O5: bone height lingually  0.37 0.52 -0.66,1.40 0.480 
O6: bone width  0.09 0.59 -1.06,1.24 0.879 
O7: %bone width  1.90 5.80 -9.47,13.27 0.743 
      
      
MD, mean difference; SE, standard error; CI, confidence interval; O, outcome; est., estimate; Adj., adjusted;S, study; C, comparison; ALL, allograft; AUT, 
autograft; rhBMP-2/ACS, recombinant human bone morphogenetic protein-2 delivered on an Absorbable Collagen Sponge; HU, Hounsfield units; CT, 
computed tomography; rhGDF-5, recombinant human growth/differentiation factor-5; Bbw, buccal bone width; Pbw, palatal bone width; Mbh, mesial 
bone height; Dbh, distal bone height; 99mTc-MDP, 99mTc-methylene diphosphonate; DFDBA, demineralized freeze-dried bone allograft; FDBA, 
mineralized freeze-dried bone allograft. 
Study MD (95% CI) Weight 
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-13.79 (-23.53, -4.05) 
-7.33 (-12.03, -2.63) 
-1.88 (-5.68, 1.92) 
-4.42 (-9.75, 0.91) 
-4.58 (-12.75, 3.59) 
-21.62 (-56.40, 13.16) 
25.33 (13.59, 37.07) 
25.33 (13.59, 37.07) 
9.04 (6.45, 11.63) 
-6.19 (-9.09, -3.29) 
-6.08 (-19.96, 7.80) 
-4.71 (-17.67, 8.25) 
11.18 (-0.83, 23.19) 











0.01 (-0.93, 0.95) 
-6.00 (-19.42, 7.41) 








% of newly-formed bone 
More % bone in the first category More % bone in the second category 
Appendix 11. Direct comparisons from the primary outcome network (mean differences and 95% confidence intervals). MD, mean 
difference; CI, confidence interval; P, parallel; ESP, extraction socket preservation; C, cluster; SL, sinus lift; LRA, lateral ridge 
augmentation; AUT, autograft; ALL, allograft; SYN, synthetic bone graft; XEN, xenograft. 



























15.3 32.1 2.9 19.9 29.7 
2 2 2 1 5 
17.4 14.0 3.4 25.6 39.6 
31.3 33.4 0.7 34.0 0.6 AUT-ALL 
7.3 81.8 1.8 7.3 1.8 AUT-SYN 
3.8 42.1 4.5 3.7 45.8 AUT-XEN 
28.3 27.7 0.6 42.6 0.7 ALL-SYN 
0.5 6.1 6.5 0.7 86.3 SYN-XEN 
ALL-XEN 
AUT-ALL AUT-SYN AUT-XEN ALL-SYN SYN-XEN 
Appendix 12. Contribution plot of each direct comparison to the evidence network. AUT, autograft; ALL, allograft; SYN, synthetic bone 
graft; XEN, xenograft. 
Appendix 13. Evaluation of transitivity across network in terms of similarities across comparisons. Presented are the mean patient ages 
(in years) and the mean sex distribution across the studies included in each comparison in the format: number of trials with provided 
data: mean (standard deviation)  
1: 52.0 (-) 
1: 45% (-) 
Mean age (in years) 
% of patients male 
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Appendix 14. League table with all direct (white) and mixed (light blue) comparisons from the primary 
























- 0.90 (-8.75,10.55) XEN 






AUT-ALL-SYN 24.57 (2.07,47.07) 40.79 
AUT-SYN-XEN 15.70 (0.00,41.43) 111.71 
    
0 2 5 20 50 
Appendix 15. Evaluation of inconsistency using loop-specific heterogeneity estimates. IF, inconsistency factor; SE, standard error; CI, 
confidence interval; AUT, autograft; ALL, allograft; SYN, synthetic bone graft; XEN, xenograft. 
Loop IF SE for IF z P value 95% CI Loop-specific tau2 
AUT-ALL-SYN 24.57 11.48 2.14 0.032 2.07,47.07 40.79 
AUT-SYN-XEN 15.70 13.13 1.20 0.232 0.00, 41.43 111.71 
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Appendix 16. Node-splitting analysis of direct and indirect comparisons. 
 Direct Indirect Difference 
Side MD SE MD SE MD SE P 
AUT-ALL -6.15 7.55 -33.63 12.91 27.48 14.95 0.066 
AUT-SYN -4.59 9.16 -6.48 9.11 1.89 12.92 0.884 
AUT-XEN -19.60 9.07 1.57 8.55 -21.16 12.49 0.090 
ALL-SYN 25.21 11.76 -3.55 9.47 28.76 15.11 0.057 
SYN-XEN 0.83 5.43 -20.15 11.51 20.97 12.71 0.099 
MD, mean difference; SE, standard error; AUT, autograft; ALL, allograft; SYN, 
synthetic bone graft; XEN, xenograft.  
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Appendix 17. Results of the original analysis and of network meta-regressions including possible confounders (using the 
ML method instead of the original REML one). Factors with considerable effects were re-analyzed with the original REML 
method and treatment rankings adjusted for this covariate were calculated. 
    Subgroup analysis  Sensitivity analysis 












 RLRT 76.15  49.61 0.000  53.03 10.45 43.41 
 P value 0.001  0.000 1.000  0.000 0.001 0.000 
















 Ranking   Ranking     
% new bone 
AUT   XEN  - - - 
SYN  - AUT  - - - 
XEN  - SYN  - - - 
ALL  - ALL  - - - 
         
% residual graft 
XEN  - 
Same 
 - - - 
AUT  -  - - - 
SYN  -  - - - 
ALL  -  - - - 
         
% connective 
tissue 
AUT  - 
Same 
 - - - 
ALL  -  - - - 
XEN  -  - - - 
SYN  -  - - - 
ML, maximum likelihood; REML, restricted maximum likelihood; RLRT, restricted likelihood ratio testing; AUT, 
autograft; ALL, allograft; SYN, synthetic bone graft; XEN, xenograft. 
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Appendix 18. Details for the GRADE assessment for each pairwise comparison and the evidence network. 
Comparison Study limitations Indirectness Inconsistency Imprecision Publication bias 
AB 
No downgrade; less than 10% in 
high risk of bias 
No robust reason to 
downgrade 
Node-splitting yielded an almost statistically significant 
difference between direct and indirect estimates, which 
influenced however their magnitude, but not their 
direction; additionally, no source of heterogeneity was 
identified through network meta-regression; decided 
not to downgrade 
Downgrade for imprecision; predictive 
intervals for treatment effect include 
effects that would have different 
interpretations 
No robust reason to 
downgrade 
AC 
No downgrade; less than 10% in 
high risk of bias 
No robust reason to 
downgrade 
No robust evidence of inconsistency 
Downgrade for imprecision; predictive 
intervals for treatment effect include 
effects that would have different 
interpretations 
No robust reason to 
downgrade 
AD 
Downgraded by two levels; 
almost half of the evidence in high 
risk of bias 
No robust reason to 
downgrade 
Node-splitting yielded an almost statistically significant 
difference between direct and indirect estimates, which 
influenced both their magnitude and their direction; 
additionally, no source of heterogeneity was identified 
through network meta-regression; decided to 
downgrade by one 
Downgrade for imprecision; predictive 
intervals for treatment effect include 
effects that would have different 
interpretations 
No robust reason to 
downgrade 
BC 
No downgrade; less than 10% in 
high risk of bias 
No robust reason to 
downgrade 
Node-splitting yielded an almost statistically significant 
difference between direct and indirect estimates, which 
influenced both their magnitude and their direction; 
additionally, no source of heterogeneity was identified 
through network meta-regression; decided to 
downgrade by one 
Downgrade for imprecision; predictive 
intervals for treatment effect include 
effects that would have different 
interpretations 
No robust reason to 
downgrade 
BD 
Downgrade by one level; one third 
of the evidence in high risk of bias 
No robust reason to 
downgrade 
Only indirect evidence available 
Downgrade for imprecision; predictive 
intervals for treatment effect include 
effects that would have different 
interpretations 
No robust reason to 
downgrade 
CD 
Downgraded by two levels; most 
evidence in high risk of bias 
No robust reason to 
downgrade 
Node-splitting yielded an almost statistically significant 
difference between direct and indirect estimates, which 
influenced both their magnitude and their direction; 
additionally, no source of heterogeneity was identified 
through network meta-regression; decided to 
downgrade by one 
Downgrade for imprecision; predictive 
intervals for treatment effect include 
effects that would have different 
interpretations 
No robust reason to 
downgrade 
Ranking 
Downgrade by one level; one third 
of the evidence in high risk of bias 
No robust reason to 
downgrade; membrane use 
could possibly have a 
modifying effect, but this 
was discarded due to lack of 
credibility 
Global Q test for inconsistency was almost statistically 
significant (P=0.061); however, model fit with the 
design-by-treatment model was not greatly improved 
and treatment ranking was relatively robust; decided 
not to downgrade 
No robust reason to downgrade 
No robust reason to 
downgrade 





















































Appendix 19. Study limitations for each network estimate for each pairwise comparison and for the whole network of %new bone. A, 
autograft; B, allograft; C, synthetic bone graft; D, xenograft. 
AB   
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AUT ALL Algipore Biogran 
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Appendix 21. Plots of the surface under the cumulative ranking curves for all treatments in the primary outcome alternative network. 
AUT, autograft; ALL, allograft; XEN, xenograft. 
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Appendix 22. Investigation of heterogeneity sources: effect of covariates on the % of new bone from individual patient 
data. 
Factor Comparison Studies MD (95% CI) P I2 (95% UI) 95% PrI 
Patient age One yr increase 4 -0.07 (-0.45, 0.31) 0.707 71% (0%,88%) -1.66,1.52 
Patient sex Male-female 3 4.79 (-3.40,12.98) 0.252 53% (0%,85%) -81.14,90.72 
Healing time One mo increase 4 2.06 (-3.03,7.15) 0.427 26% (0%,76%) -13.92,18.04 
Membrane type EPTFE-ADMA 1 -13.64 (-26.67,-0.61) 0.040 - - 
MD, mean difference; CI, confidence interval; UI, uncertainty interval; PrI, predictive interval; EPTFE, expanded 
polytetrafluoroethylene; ADMA, acellular dermal matrix allograft. 
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Appendix 23. Direct estimates for the secondary histomorphometric outcomes. 
Connective tissue 
Comparison Studies MD (95% CI) I2 (95% UI) tau2 95% PrI P 
AUT-ALL 2 1.76 (-2.29.5.80) 0% (-) 0.00 - 0.395 
AUT-SYN 2 14.67 (-7.10,36.43) 98% (-) 241.96 - 0.187 
AUT-XEN 2 -1.24 (-11.19,8.71) 0% (-) 0.00 - 0.807 
ALL-SYN 1 17.73 (5.70,29.76) - 0.00 - 0.004 
SYN-XEN 5 1.00 (-5.50,7.50) 69% (0%,86%) 34.42 -20.45,22.45 0.763 
       
Residual graft 
AUT-ALL 2 8.14 (-6.87,23.15) 85% (-) 100.77 - 0.288 
AUT-SYN 1 5.50 (3.52,7.48) - 0.00 - <0.001 
AUT-XEN 1 -2.12 (-11.74,7.50) - 0.00 - 0.666 
ALL-SYN 1 -9.57 (-12.75,-6.39) - 0.00 - <0.001 
SYN-XEN 5 -1.96 (-13.54,9.62) 95% (91%,96%) 160.53 -46.45,9.62 0.740 
       
MD, mean difference; CI, confidence interval; UI, uncertainty interval; PrI, predictive interval; AUT, 
autograft; ALL, allograft; SYN, synthetic bone graft; XEN, xenograft. 
Residual graft Connective tissue 
Appendix 24. Network plots and contribution plots for the secondary histomorphometric outcomes. A, AUT (autograft); B, ALL 
(allograft); C, SYN (synthetic bone graft); D, XEN (xenograft). 



























1.9 35.9 18.8 30.1 13.3 
2 1 1 1 5 
3.0 47.3 0.8 48.1 0.8 
1.6 93.6 1.6 1.6 1.6 
0.5 28.1 42.5 0.4 28.5 
4.0 4.0 0.1 91.8 0.1 
0.6 35.9 36.5 0.7 26.3 
2.0 21.0 23.0 37.5 16.5 







29.6 5.0 22.9 16.8 25.8 
2 2 2 1 5 
84.9 1.3 4.2 5.5 4.2 
21.7 7.4 24.6 21.6 24.7 
17.1 5.8 37.4 17.0 22.8 
27.5 6.3 21.2 23.8 21.2 
9.4 3.2 12.6 9.4 65.4 
31.5 3.9 27.6 16.5 20.4 
AvsB AvsC AvsD BvsC CvsD 
Residual graft Connective tissue 
1 
Appendix 25. League table with all mixed comparisons from the primary outcome network (mean differences and 95% 
confidence intervals. 
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Appendix 26. Ranking of various grafts according to the networks for the secondary histomorphometric outcomes of % residual graft 
and % connective tissue. AUT, autograft; ALL, allograft; SYN, synthetic bone graft; XEN, xenograft; SUCRA, surface under the 
cumulative ranking curve. 
  % Residual graft   % Connective tissue 
Rank AUT ALL SYN XEN   AUT ALL SYN XEN 
Best 40.4 3.2 14.7 41.9   44.5 52.2 0.3 3.1 
Mean 
rank 
2.0 3.6 2.5 1.9   1.6 1.6 3.7 3.1 


































Appendix 27. Clustered ranking plot of the graft network based on cluster analysis of SUCRA values for two different outcomes: % new 
bone and % residual graft. AUT, autograft; SYN, synthetic bone graft; XEN, xenograft; ALL, allograft. 
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Appendix 28. Node-splitting analysis of direct and indirect comparisons for the secondary histomorphometric outcomes. 
 Residual graft  Connective tissue 
 Direct Indirect Difference  Direct Indirect Difference 
Side MD SE MD SE MD SE P  MD SE MD SE MD SE P 
AUT-ALL 8.25 8.33 11.94 13.61 -3.69 15.97 0.817  1.95 6.62 -8.51 11.83 10.46 13.56 0.440 
AUT-SYN 5.50 1.00 -0.77 8.90 6.27 14.15 0.658  14.57 6.32 5.42 7.09 9.15 9.50 0.336 
AUT-XEN -2.12 12.09 0.37 9.53 -2.49 15.39 0.872  -1.13 7.43 15.49 6.32 -16.62 9.76 0.088 
ALL-SYN -9.57 11.18 -5.37 11.64 -4.19 16.14 0.795  17.71 10.78 6.97 8.44 10.74 13.70 0.433 
SYN-XEN -1.97 5.23 -4.86 14.83 2.89 15.72 0.854  0.74 4.01 -16.83 8.96 17.56 9.80 0.073 
MD, mean difference; SE, standard error; AUT, autograft; ALL, allograft; SYN, synthetic bone graft; XEN, xenograft . 
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Appendix 29. Communications with authors of trials. 












Cordaro L, Bosshardt DD, Palattella P, Rao W, Serino G, Chiapasco M. Maxillary sinus grafting with Bio-Oss or Straumann Bone Ceramic: histomorphometric results from a 







Corinaldesi G, Piersanti L, Piattelli A, Iezzi G, Pieri F, Marchetti C. Augmentation of the floor of the maxillary sinus with recombinant human bone morphogenetic protein-








-Crespi R, Cappare P, Gherlone E. Magnesium-enriched hydroxyapatite compared to calcium sulfate in the healing of human extraction sockets: radiographic and 
histomorphometric evaluation at 3 months. J Periodontol 2009;80:210-8. 
-Crespi R, Mariani E, Benasciutti E, Cappare P, Cenci S, Gherlone E. Magnesium-enriched hydroxyapatite versus autologous bone in maxillary sinus grafting: combining 
histomorphometry with osteoblast gene expression profiles ex vivo. J Periodontol 2009;80:586-93. 
-Crespi R, Cappare P, Gherlone E. Comparison of magnesium-enriched hydroxyapatite and porcine bone in human extraction socket healing: a histologic and 




5 Felice 2008 
Felice P, Marchetti C, Piattelli A, Pellegrino G, Checchi V, Worthington H, et al. Vertical ridge augmentation of the atrophic posterior mandible with interpositional block 







Kotsakis GA, Salama M, Chrepa V, Hinrichs JE, Gaillard P. A randomized, blinded, controlled clinical study of particulate anorganic bovine bone mineral and calcium 
phosphosilicate putty bone substitutes for socket preservation. Int J Oral Maxillofac Imp 2014;29:141-51. 
Data 
Responded; 
sent raw data 
7 Molly 2008 








Mordenfeld A, Johansson CB, Albrektsson T, Hallman M. A randomized and controlled clinical trial of two different compositions of deproteinized bovine bone and 







Raghoebar GM, Schortinghuis J, Liem RS, Ruben JL, van der Wal JE, Vissink A. Does platelet-rich plasma promote remodeling of autologous bone grafts used for 







Schmitt CM, Doering H, Schmidt T, Lutz R, Neukam FW, Schlegel KA. Histological results after maxillary sinus augmentation with Straumann(R) BoneCeramic, Bio-Oss(R), 







Wagner W, Wiltfang J, Pistner H, Yildirim M, Ploder B, Chapman M, et al. Bone formation with a biphasic calcium phosphate combined with fibrin sealant in maxillary 







Wiltfang J, Schlegel KA, Schultze-Mosgau S, Nkenke E, Zimmermann R, Kessler P. Sinus floor augmentation with beta-tricalciumphosphate (beta-TCP): does platelet-rich 







-Cannizzaro G, Felice P, Leone M, Viola P, Esposito M. Early loading of implants in the atrophic posterior maxilla: lateral sinus lift with autogenous bone and Bio-Oss 
versus crestal mini sinus lift and 8-mm hydroxyapatite-coated implants. A randomised controlled clinical trial. Eur J Oral Implantol 2009;2:25-38. 
-Cannizzaro G, Felice P, Minciarelli AF, Leone M, Viola P, Esposito M. Early implant loading in the atrophic posterior maxilla: 1-stage lateral versus crestal sinus lift and 8 
mm hydroxyapatite-coated implants. A 5-year randomised controlled trial. Eur J Oral Implantol 2013;6:13-25. 
-Esposito M, Cannizzaro G, Soardi E, Pellegrino G, Pistilli R, Felice P. A 3-year post-loading report of a randomised controlled trial on the rehabilitation of posterior 
atrophic mandibles: short implants or longer implants in vertically augmented bone? Eur J Oral Implantol 2011;4:301–311. 
-Esposito M, Cannizzaro G, Soardi E, Pistilli R, Piattelli M, Corvino V, Felice P. Posterior atrophic jaws rehabilitated with prostheses supported by 6 mm-long, 4 mm-wide 
implants or by longer implants in augmented bone. Preliminary results from a pilot randomised controlled trial. Eur J Oral Implantol 2012;5:19-33. 
-Esposito M, Piattelli M, Pistilli R, Pellegrino G, Felice P. Sinus lift with guided bone regeneration or anorganic bovine bone: 1-year post-loading results of a pilot 
randomised clinical trial. Eur J Oral Implantol 2010;3:297-305. 
-Felice P, Scarano A, Pistilli R, Checchi L, Piattelli M, Pellegrino G, Esposito M. A comparison of two techniques to augment maxillary sinuses using the lateral window 
approach: rigid synthetic resorbable barriers versus anorganic bovine bone. Five-month post-loading clinical and histological results of a pilot randomised controlled 





14 Lee 2008 
Lee CY, Rohrer MD, Prasad HS. Immediate loading of the grafted maxillary sinus using platelet rich plasma and autogenous bone: a preliminary study with histologic and 







Appendix 30. Additional information regarding this systematic review. 
 
Author contributions 
SNP conceived the idea and wrote the first draft of the protocol. SNP, PNP, JD, WG revised the protocol. 
SNP performed the literature searches, extracted search hits, and did screening by title. SNP, PNP, and JD 
did study selection by abstract and full-text, did data extraction, and assessed the risk of bias in triplicate, 
while WG resolved any conflicts that arose. SNP handled communications with trialists, performed the 
statistical analysis (individual patient data processing, pairwise and network meta-analyses), and wrote 
the first draft of the manuscript. SNP, PNP, JD, and WG assisted in the interpretation of the results and 
revised the manuscript draft. SNP submitted the manuscript, is the guarantor and responsible for the 
accuracy of the data and for future updates of the review. 
 
Post hoc changes to the protocol 
 Smoking was not tested in the investigation for heterogeneity sources, as during piloting of the 
literature, strong evidence of impaired wound and bone healing was not found for smoking from 
re-analysis of raw data and was decided that this did not pertain to uninterrupted physiological 
graft healing. 
 The method of measuring the outcome was not tested in the investigation for heterogeneity 
sources, as all studies used similar procedures. 
 Many secondary outcomes listed in the protocol not pertaining to histomorphometry were not 
included in the review. Due to the heavy number of reported outcomes, which would make this 
review difficult to present and read, we focused only on the primary outcome 
(histomorphometrical %new bone) and the two most often-reported histomorphometrical 
secondary outcomes from the protocol (%residual graft and %connective tissue). All outcomes 
however reported from include trials are analyzed and reported in Appendix 10. 
 We had planned to restrict analyses to studies with use of membrane and a minimum of 4 
months of uninterrupted healing. As however no differences were found for membrane use from 
our analyses and all studies had 6 or more months of healing, this was discarded. 
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